<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002822.pub3" GROUP_ID="MUSKEL" ID="370800031008501350" MERGED_FROM="" MODIFIED="2008-11-13 08:16:08 +0100" MODIFIED_BY="Elizabeth Tanjong Ghogomu" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.3&lt;/p&gt;&lt;p&gt;Old title: Physiotherapy interventions for ankylosing spondylitis&lt;br&gt;Old title: Physiotherapy interventions for Ankylosing Spondylitis&lt;br&gt;Old title: physiotherapy interventions for ankylosing spondylitis&lt;br&gt;Old title: Physiotherapy interventions for ankylosing spondylitis&lt;/p&gt;" NOTES_MODIFIED="2008-09-15 16:14:38 -0400" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="C066-R" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2008-09-15 16:14:24 -0400" MODIFIED_BY="[Empty name]">
<TITLE>Physiotherapy interventions for ankylosing spondylitis</TITLE>
<CONTACT>
<PERSON ID="14920" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Hanne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Dagfinrud</LAST_NAME>
<SUFFIX/>
<POSITION>Research fellow</POSITION>
<EMAIL_1>h.s.dagfinrud@medisin.uio.no</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Section for Health Science</DEPARTMENT>
<ORGANISATION>University of Oslo</ORGANISATION>
<ADDRESS_1>P.O.box 1153, Blindern</ADDRESS_1>
<ADDRESS_2>Gydas vei 8</ADDRESS_2>
<CITY>Oslo</CITY>
<ZIP>0316</ZIP>
<REGION/>
<COUNTRY CODE="NO">Norway</COUNTRY>
<PHONE_1>+4722858428</PHONE_1>
<PHONE_2>+4741906633</PHONE_2>
<FAX_1>+4722858411</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-09-15 16:04:54 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="14920" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Hanne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Dagfinrud</LAST_NAME>
<SUFFIX/>
<POSITION>Research fellow</POSITION>
<EMAIL_1>h.s.dagfinrud@medisin.uio.no</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Section for Health Science</DEPARTMENT>
<ORGANISATION>University of Oslo</ORGANISATION>
<ADDRESS_1>P.O.box 1153, Blindern</ADDRESS_1>
<ADDRESS_2>Gydas vei 8</ADDRESS_2>
<CITY>Oslo</CITY>
<ZIP>0316</ZIP>
<REGION/>
<COUNTRY CODE="NO">Norway</COUNTRY>
<PHONE_1>+4722858428</PHONE_1>
<PHONE_2>+4741906633</PHONE_2>
<FAX_1>+4722858411</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12689" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kåre Birger</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hagen</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Researcher</POSITION>
<EMAIL_1>k.b.hagen@medisin.uio.no</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>National Resource Centre for Rehabilitation in Rheumatology</DEPARTMENT>
<ORGANISATION>Diakonhjemmet Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2>PO Box 23 Vindern</ADDRESS_2>
<CITY>0319 Oslo</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NO">Norway</COUNTRY>
<PHONE_1>+(47) 22454855</PHONE_1>
<PHONE_2>+47 22 45 48 50</PHONE_2>
<FAX_1>+ 47 24 16 32 75</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19682" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Tore</FIRST_NAME>
<MIDDLE_INITIALS>K</MIDDLE_INITIALS>
<LAST_NAME>Kvien</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>t.k.kvien@medisin.uio.no</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Rheumatology</DEPARTMENT>
<ORGANISATION>Diakonhjemmet Hospital</ORGANISATION>
<ADDRESS_1>P.O box 23, Vinderen</ADDRESS_1>
<ADDRESS_2>Borgenveien 3c</ADDRESS_2>
<CITY>Oslo</CITY>
<ZIP>0319</ZIP>
<REGION/>
<COUNTRY CODE="NO">Norway</COUNTRY>
<PHONE_1>0047 22451500</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-09-15 16:05:32 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 11/14/07&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 6/20/07&lt;/p&gt;&lt;p&gt;Conclusions changed: 11/14/07&lt;/p&gt;&lt;p&gt;Reformatted: 11/14/07&lt;/p&gt;" NOTES_MODIFIED="2008-09-15 16:05:32 -0400" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="20" MONTH="6" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="6" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="11" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2008-09-15 16:14:24 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Compared to the previous version of this review, substantial changes have been made. Eleven trials with a total of 763 participants were included in this updated review as compared to six trials and 561 patients in the previous version. The different types of interventions are also expanded, now including seven studies comparing different modalities or applications of physiotherapy. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-09-15 16:14:24 -0400" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-09-15 16:14:24 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
<P>CMSG ID: C066-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>The University of Oslo</NAME>
<COUNTRY CODE="NO">Norway</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Diakonhjemmet Hospital</NAME>
<COUNTRY CODE="NO">Norway</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>The National Foundation for Postgraduate Physiotherapists</NAME>
<COUNTRY CODE="NO">Norway</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Physiotherapy for ankylosing spondylitis</TITLE>
<SUMMARY_BODY>
<P>
<B>How well does physical therapy work for treating ankylosing spondylitis and how safe is it?</B>
<BR/>To answer this question, scientists working with the Cochrane Musculoskeletal Group found and analyzed 11 studies testing over 700 people who had ankylosing spondylitis (AS). Studies compared people who did exercises at home, went to group exercise programs, went to spa or balneotherapy, performed different exercise programs or had no therapy at all. These studies provide the best evidence we have today.</P>
<P>
<B>What is ankylosing spondylitis and how can physical therapy help?</B>
<BR/>AS is a type of arthritis most typically affecting the joints and ligaments of the spine, and results in varying degree of pain, stiffness and disability. Physiotherapy is an important treatment to maintain or improve movement in the spine, improve fitness and decrease pain. </P>
<P>
<B>How well does physical therapy work?</B>
<BR/>Four studies compared individual or supervised exercises to no therapy at all. They found that both individual and supervised exercise programs improve spinal movement more than no therapy. The exercise programs were done for two to six months. <BR/>Three studies compared home exercises to supervised group exercises. They found that group exercises improve movement in the spine and overall well-being, but did not improve self-reported physical function more than home exercises. Exercises were done for three weeks to nine months, and included strengthening, aerobic exercises, hydrotherapy, sports activities and stretching.<BR/>One study compared two groups who both did weekly group exercises for 10 months, but one of the groups also went to a spa resort for three weeks of physiotherapy. Spa therapy plus weekly group exercises improves pain and overall well-being more than just weekly group exercises. One study compared balneotherapy and daily exercises with only daily exercises, and another study compared balneotherapy with fresh water therapy. Both these studies showed improvements after treatment for several outcomes, but no significant differences between the groups were found. One study compared a four-month experimental exercise program with a conventional program. Both groups improved, but the experimental exercise group improved more on spinal mobility and physical function than the conventional exercise group.</P>
<P>
<B>Did physical therapy harm patients?</B>
<BR/>Harms to the patients were not reported in the studies.</P>
<P>
<B>What is the bottom line?</B>
<BR/>Physiotherapy or exercises are helpful to people with ankylosing spondylitis. </P>
<P>There is "silver" level evidence (www.cochranemsk.org) that exercise programs, home-based or supervised, are better than no exercises and improve movement and physical function. Group exercises are better than home exercises, and improve movement and overall well-being. Adding a few weeks of exercising at a spa resort to weekly group exercises is better than just weekly group exercises. Balneotherapy in addition to exercise program did not show additional effect, nor did balneotherapy compared to fresh water therapy. An experimental exercise program showed more improvement on mobility and physical function than conventional exercises, but differences between groups were not statistically significant. We still need more information about the different types of physiotherapy and exercise, and how long, how intensive and how often physiotherapy should be done for the most improvement.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Ankylosing spondylitis (AS) is a chronic, inflammatory rheumatic disease. Physiotherapy is considered an important part of the overall management of AS.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To summarise the available scientific evidence on the effectiveness of physiotherapy interventions in the management of AS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, AMED, CINAHL and PEDro up to January 2007 for all relevant publications, without any language restrictions. We checked the reference lists of relevant articles and contacted the authors of included articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included randomised and quasi-randomised studies with AS patients and where at least one of the comparison groups received physiotherapy. The main outcomes of interest were pain, stiffness, spinal mobility, physical function and patient global assessment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently selected trials for inclusion, extracted data and assessed trial quality. Investigators were contacted to obtain missing information.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Eleven trials with a total of 763 participants were included in this updated review. <BR/>Four trials compared individualised home exercise programs or a supervised exercise program with no intervention and reported low quality evidence for effects in spinal mobility (Relative percentage differences (RPDs) from 5-50%) and physical function (four points on a 33-point scale). <BR/>Three trials compared supervised group physiotherapy with an individualised home-exercise program and reported moderate quality evidence for small differences in spinal mobility (RPDs 7.5-18%) and patient global assessment (1.46 cm) in favour of supervised group exercises. <BR/>In one study, a three-week inpatient spa-exercise therapy followed by 37 weeks of weekly outpatient group physiotherapy (without spa) was compared with weekly outpatient group physiotherapy alone; there was moderate quality evidence for effects in pain (18%), physical function (24%) and patient global assessment (27%) in favour of the combined spa-exercise therapy. One study compared daily outpatient balneotherapy and an exercise program with only exercise program, and another study compared balneotherapy with fresh water therapy. None of these studies showed significant between-group differences. One study compared an experimental exercise program with a conventional program; statistically significant change scores were reported on nearly all spinal mobility measures and physical function in favour of the experimental program.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The results of this review suggest that an individual home-based or supervised exercise program is better than no intervention; that supervised group physiotherapy is better than home exercises; and that combined inpatient spa-exercise therapy followed by group physiotherapy is better than group physiotherapy alone.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Ankylosing spondylitis (AS) is a chronic, progressive, inflammatory disorder mainly affecting the axial skeleton with aseptic inflammation of synovial tissue, spinal ligaments, intervertebral discs and facet joints. It is characterised clinically by pain and stiffness of the back and the sacroiliac joints, and is frequently also associated with peripheral arthritis, enthesitis and acute anterior uveitis (<LINK REF="REF-Khan-2002" TYPE="REFERENCE">Khan 2002</LINK>; <LINK REF="REF-Sieper-2002" TYPE="REFERENCE">Sieper 2002</LINK>). The aetiology of AS is unknown. The estimated prevalence in European Caucasian populations is 0.1 to 1.2% and the male to female ratio is about 2-3:1 (<LINK REF="REF-Dougados-1995" TYPE="REFERENCE">Dougados 1995</LINK>; <LINK REF="REF-Gran-1993" TYPE="REFERENCE">Gran 1993</LINK>; <LINK REF="REF-Robbins-2001" TYPE="REFERENCE">Robbins 2001</LINK>; <LINK REF="REF-Sieper-2006" TYPE="REFERENCE">Sieper 2006</LINK>). AS leads to variable degrees of pain, reduced spinal mobility and limitations in physical functioning. Physiotherapy is, therefore, considered important to maintain or improve spinal mobility and fitness and to reduce pain, and is included in the recently published evidence based recommendations for management of AS (<LINK REF="REF-Zochling-2006" TYPE="REFERENCE">Zochling 2006</LINK>). </P>
</BACKGROUND>
<OBJECTIVES>
<P>The purpose of this review was to assess the effectiveness of various physiotherapy interventions (active and passive modalities) in the management of patients with AS. </P>
<P>The following main comparisons were made: <BR/>1. physiotherapy versus other interventions (including no intervention);<BR/>2. comparison of different modalities or applications of physiotherapy.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised or quasi-randomised controlled studies examining the effectiveness of physiotherapy in AS.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Males and females with the diagnosis of AS according to the classification system described in the modified New York criteria (<LINK REF="REF-Van-der-Linden-1984" TYPE="REFERENCE">Van der Linden 1984</LINK>). We excluded trials if the diagnostic criteria were unsure or not met.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We included studies if the intervention included any physiotherapy modality considered relevant in the management of AS. If co-interventions were included, they had to be similar in the comparator groups. The relevant physiotherapy modalities in the management of AS include: supervised and unsupervised exercises, training, manual therapy, massage, hydrotherapy, electrotherapy, acupuncture, patient information and educational programs.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The study group for Assessment in AS (ASAS) has suggested a core set of outcome measures in physiotherapy (<LINK REF="REF-Van-der-Heijde-1999" TYPE="REFERENCE">Van der Heijde 1999</LINK>). Studies which have any of these outcome measures were included in the review. <BR/>
</P>
<UL>
<LI>Pain </LI>
<LI>Stiffness </LI>
<LI>Spinal mobility </LI>
<LI>Physical function </LI>
<LI>Patient global assessment </LI>
<LI>Other relevant outcome measures</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>We identified relevant studies by searching the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, AMED, CINAHL and PEDro up to January 2007. <BR/>We used the search strategies recommended in the Cochrane Reviewers' Handbook 4.2.6 (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>). The reference lists of retrieved studies were scanned to identify additional relevant trials, and authors of relevant studies were contacted for additional information. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Two of the reviewers (HD and KBH) independently selected trials included in the review, using a standard pre-developed form that was pilot-tested. </P>
<P>
<B>Methodological quality </B>
<BR/>HD and KBH also independently assessed the methodological quality of the included studies. Disagreement was easily resolved by discussion. We assessed internal validity using criteria according to the Cochrane Reviewers' Handbook (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>). We used the following five criteria in assessment:<BR/> <BR/>1. concealment of allocation;<BR/>2. co-intervention;<BR/>3. intention-to-treat analysis and losses to follow up; <BR/>4. outcome assessment;<BR/>5. blinding of patients.</P>
<P>These five criteria were rated as "MET", "UNCLEAR" or "NOT MET". Blinding of providers is clearly not possible, so the criteria focus upon blinding of assessors and patients. </P>
<P>
<B>Operationalisation of the five methodological quality criteria<BR/> </B>
<BR/>
<B>
<I>1. Concealment of allocation</I>
</B>
<I> <BR/>
</I>Met: use of a centralised (e.g. group assignment by a central office unaware of participant characteristics); on-site computer system combined with group assignments in a locked unreadable computer file that could be accessed only after entering of an enrolled participant; sequentially numbered, sealed, opaque envelopes; i.e. the randomisation was independent of provider and investigator. <BR/>Unclear: concealment approach not reported and could not be verified by contacting the investigators. <BR/>Not met: included alternation, case record numbers, dates of birth, day of week, and any allocation procedure that was entirely transparent before assignment such as open list of random numbers of assignments. <BR/>
<B>
<BR/>
</B>
<B>
<I>2. Co-intervention</I>
</B>
<I> <BR/>
</I>Met: interventions other than those compared were avoided or used similarly across comparison groups. <BR/>Unclear: co-interventions not reported and could not be verified by contacting investigators. <BR/>Not met: dissimilar use of interventions other than physiotherapy. <BR/>
<B>
<BR/>
</B>
<B>
<I>3. Intention-to-treat analysis and losses to follow up</I>
</B>
<I> <BR/>
</I>Met: intention-to-treat analysis performed AND losses to follow up less than 20% and equally distributed between comparison groups. <BR/>Unclear: intention-to-treat analysis or losses to follow up not reported and could not be verified by contacting the authors. <BR/>Not met: exclusion not reported and could not be verified by contacting the investigators AND losses to follow up greater than 20%. </P>
<P>
<B>
<I>4. Outcome assessment </I>
</B>
<I>
<BR/>
</I>Met: assessors unaware of the assigned treatment when collecting outcome measures. <BR/>Unclear: blinding of assessor not reported, and could not be verified by contacting the investigators. <BR/>Not met: assessor aware of the assigned treatment when collecting outcome measures. <BR/>
<B>
<BR/>
</B>
<B>
<I>5. Blinding of patients<BR/>
</I>
</B>Met: patients unaware of the assigned treatment.<BR/>Unclear: blinding of patients not reported.<BR/>Not met: patients aware of the assigned treatment or blinding of patient not possible.</P>
<P>An overall assessment of internal validity was based on a summary of these five criteria: low risk of bias meant that four out of five criteria were met; moderate risk of bias meant that three criteria were met; and high risk of bias meant that fewer than three criteria were met. </P>
<P>
<B>Data extraction and analyses </B>
<BR/>Two reviewers (KBH and HD) independently extracted data by using a pilot-tested data extraction form. Disagreement was resolved by discussion. If the article did not provide sufficient information for methodological assessment or necessary data for statistical analyses letters were sent to investigators to collect missing data. We sent six letters, and four of the authors replied to our request. Two provided additional information regarding methodological quality and two provided additional data for statistical analyses. <BR/>
<B>
<BR/>Analyses </B>
<BR/>For the first main comparison of physiotherapy interventions versus other interventions or no intervention the pre-planned analyses were:<BR/>trials comparing (individual) home-based or supervised exercise program with no intervention.</P>
<P>For the second main comparison of different modalities or applications of physiotherapy the pre-planned stratified analyses were: <BR/>a) trials comparing home exercise regimes with supervised, inpatient or outpatient group physiotherapy (including hydrotherapy);<BR/>b) trials comparing inpatient spa-exercise therapy with supervised, weekly group physiotherapy;<BR/>c) trials comparing balneotherapy and exercises with exercises alone;<BR/>d) trials comparing balneotherapy with fresh water therapy;<BR/>e) trials comparing an experimental muscle chain exercise program with a conventional exercise program.</P>
<P>The various outcome measures are presented separately (see Graphs 01.01 to 07.02). Since all outcomes were continuous variables, results are expressed, if possible, as weighted mean differences (WMD) with corresponding 95 percent confidence intervals (CI) (<LINK REF="REF-Deeks-J-2004" TYPE="REFERENCE">Deeks J 2004</LINK>). </P>
<P>Due to insufficient data reporting, overall effects could be calculated only for two outcomes in one comparison. Both outcomes were measured with identical instruments across studies and WMDs were calculated. Both random-effect and fixed-effect models were employed. For the other comparisons and outcomes only data from single studies provided data for statistical analyses. For studies not providing sufficient data, we undertook qualitative analyses. In one trial (<LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>) two interventions were considered clinically similar and were, therefore, combined for analytical purposes. </P>
<P>
<B>Clinical relevance</B> <BR/>In order to improve the clinical relevance of the review, we calculated absolute benefit and relative percentage differences (RPD). Absolute benefit was calculated as the improvement in the treatment group less the improvement in the control group using the original units. RPD was calculated as the absolute benefit divided by the baseline mean in the control group. According to the <LINK REF="REF-Philadelphia-Panel" TYPE="REFERENCE">Philadelphia Panel</LINK>, an improvement at 15% relative to a control group was considered clinically relevant (presented in 'Additional tables'). </P>
<P>
<B>Quality of evidence</B> <BR/>Finally, we assessed the quality of evidence according to a recently developed systematic and explicit method (<LINK REF="REF-Grade-Working-Group" TYPE="REFERENCE">Grade Working Group</LINK>). In order to indicate the extent to which one can be confident that an estimate of effect is correct, judgments about the quality of evidence were made for each comparison and outcome. These judgments considered study design (RCT, quasi-RCT or observational study), study quality (detailed study design and execution), consistency of results (similarity of estimates of effect across studies) and directness (the extent to which people, interventions and outcome measures are similar to those of interest). The following definitions in grading the quality of evidence for each outcome were used. <BR/>High: further research is very unlikely to change our confidence in the estimate of effect. <BR/>Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <BR/>Low: further research is very likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <BR/>Very low: any estimate of effect is very uncertain. <BR/>In addition, there are some considerations that can lower or raise the quality of evidence which were not employed in this review (<LINK REF="REF-Grade-Working-Group" TYPE="REFERENCE">Grade Working Group</LINK>).</P>
<P>
<B>Grading of evidence<BR/>
</B>The grading system used is recommended by the Cochrane Musculosleletal Review Group (<LINK REF="REF-Tugwell-2004" TYPE="REFERENCE">Tugwell 2004</LINK>):</P>
<P>
<U>Platinum level<BR/>
</U>The Platinum ranking is given to evidence that meets the following criteria as reported:<BR/>a published systematic review that has at least two individual controlled trials, each satisfying the following:<BR/>"Sample sizes of at least 50 per group. If they do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome.<BR/>"Blinding of patients and assessors for outcomes. <BR/>"Handling of withdrawals &gt;80% follow up (imputations based on methods such as Last Observation Carried Forward (LOCF) acceptable). <BR/>"Concealment of treatment allocation.</P>
<P>
<U>Gold level<BR/>
</U>The Gold ranking is given to evidence if at least one randomised clinical trial meets all of the following criteria for the major outcome(s) as reported:<BR/>"Sample sizes of at least 50 per group. If they do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome.<BR/>"Blinding of patients and assessors for outcomes.<BR/>"Handling of withdrawals &gt; 80% follow up (imputations based on methods such as Last Observation Carried Forward (LOCF) acceptable).<BR/>"Concealment of treatment allocation.<BR/> <BR/>
<U>Silver level<BR/>
</U>The Silver ranking is given to evidence if randomised trial does not meet the above criteria. Silver ranking would also include evidence from at least one study of non-randomised cohorts who did and did not receive the therapy or evidence from at least one high quality case-control study. A randomised trial with a 'head-to-head' comparison of agents is considered Silver level ranking unless a reference is provided to a comparison of one of the agents to placebo showing at least a 20% relative difference. </P>
<P>
<U>Bronze level<BR/>
</U>The bronze ranking is given to evidence if there is at least one high quality case series without controls (including simple before/after studies in which the patient acts as their own control) or if it is derived from expert opinion based on clinical experience without reference to any of the foregoing (for example, argument from physiology, bench research or first principles).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>
<B>Included studies</B> <BR/>We considered 52 studies for inclusion in this review. We excluded 36 due to either study design, participants, intervention, outcome measures or insufficient data reporting (see 'Characteristics of excluded studies'). Two conference abstracts (<LINK REF="STD-Ahmad-2000" TYPE="STUDY">Ahmad 2000</LINK>; <LINK REF="STD-Pickering-2000" TYPE="STUDY">Pickering 2000</LINK>) were considered as potentially eligible, but full reports were not available (see 'Studies awaiting assessment'). Fourteen published trials were RCTs and investigated the effect of physiotherapy in the management of patients with AS (<LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>; <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>; <LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK>; <LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>; <LINK REF="REF-D_x0027_Las-Pe_x00f1_as-b2005" TYPE="REFERENCE">D'Las Peñas b2005</LINK>; <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>; <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>; <LINK REF="STD-Hidding-1994" TYPE="STUDY">Hidding 1994</LINK>; <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK>; <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>; <LINK REF="STD-Kraag-1994" TYPE="STUDY">Kraag 1994</LINK>; <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>; <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK>; <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>). However, two of these were cross-over or follow-up studies that did not provide independent results and were consequently excluded from the review (<LINK REF="STD-Hidding-1994" TYPE="STUDY">Hidding 1994</LINK>; <LINK REF="STD-Kraag-1994" TYPE="STUDY">Kraag 1994</LINK>). Eleven trials were included in the review. In addition, we have included results from one follow-up study (<LINK REF="REF-D_x0027_Las-Pe_x00f1_as-b2005" TYPE="REFERENCE">D'Las Peñas b2005</LINK>). The studies were undertaken in Canada (<LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>), the Netherlands (<LINK REF="REF-Hidding-A-1993" TYPE="REFERENCE">Hidding A 1993</LINK>), United Kingdom (<LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>; <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK> ), Austria, Germany and Netherlands (<LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>), Turkey (<LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>; <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>; <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK>), Republic of Korea (<LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>), Israel (<LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK>) and Spain (<LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>) . </P>
<P>
<B>Participants <BR/>
</B>
<LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK> included 53 patients; 79% were men. The patients were stratified according to age: 18 to 35 years, and 36 years and over. The exclusion criteria were patients with reduced hip flexion and patients receiving contravening treatment. </P>
<P>
<LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK> included 144 patients, aged between 17 and 69 years; 76% were men. Patients were excluded if they were unable to engage in physiotherapy for any reason. </P>
<P>
<LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK> conducted a study of 44 patients; 89% were men. Mean age in the inpatient, outpatient and home exercise groups were 39, 43 and 42 years respectively. The participants were stratified into two levels of disease severity. Patients were excluded if they had severe peripheral joint involvement which made them unable to exercise. </P>
<P>
<LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK> included a total of 120 patients in their trial. Mean ages in the two spa-exercise groups were 48 and 49 years, and in the control group, 48 years. In the two spa-exercise groups, the proportion of men was 67% and 70% respectively, while the control group included 85% men. The exclusion criteria were unwillingness to participate in weekly group physical therapy, pregnancy, claustrophobia, severe co-morbidity and patients having AS for more than 20 years. </P>
<P>In the study of <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK>, 155 patients between 16 and 65 years participated, 68% men in the intervention group and 66% men in the control group. Exclusion criteria were not described. </P>
<P>
<LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK> conducted a study of 45 patients aged between 18 and 55 years. Mean age was 38 years in the intervention group and 34 years in the control group. The proportion of men was 87% in the intervention group and 82% in the control group. The participants fulfilled the AMOR criteria for spondylarthropathies, which were considered equal to the New York criteria (<LINK REF="REF-Amor-1991" TYPE="REFERENCE">Amor 1991</LINK>). Patients were excluded if they had systemic organ involvement, hip or knee deformities, had been treated by a physiotherapist within the last three months, were practising regular exercises or were receiving disease-modifying anti-rheumatic drugs (DMARDs). Three studies were published in 2005. <LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK> conducted a study with 28 participants (93% men); the inclusion criteria were fulfilling NY criteria and back pain last three months prior to enrollment. Patients were excluded if they had concomitant psoriasis, other seronegative SpA, malignacies, equilibrium disturbances, mental disorders or active non-inflammatory spinal disease. </P>
<P>A study from Spain (<LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>) included 40 AS patients fulfilling NY criteria, 78% men, mean age 45.5 years. Patients were excluded if they were in functional class level IV, had comorbidity or osteoporosis.<BR/>In the Republic of Korea, a study including 50 participants, 78% men and mean age 28 years, was carried out (<LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>). The patients were included if they had been out of regular exercising previous six months, had no complications, no changes in current medication and were classified in the functional class II for AS.<BR/> <BR/>Two studies were carried out in Turkey in 2006. <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK> included 30 participants, mean age 35 years and 60% men. Inclusion and exclusion criteria not described, but the included patients fulfilled the NY criteria, and <LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK> included 54 patients, details not reported. </P>
<P>
<B>Comparisons and interventions</B> <BR/>Four studies compared physiotherapy interventions with no intervention (<LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK>; <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>; <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>; <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK>), and seven studies compared different modalities or applications of physiotherapy (<LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>; <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>; <LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK>; <LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>; <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>; <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>; <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>). </P>
<P>Exercises were the main experimental treatment in all trials, although other physiotherapy modalities were reported as 'occasionally used' (<LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>; <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>). </P>
<P>
<LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK> compared a four-month home exercise and educational program (supervised, one-to-one design) with no intervention. The educational program was not described but the treatment objectives were disease education, pain control and improved posture and function. </P>
<P>The group exercise program in the study of <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK> consisted of one hour physical training, one hour sporting activity and one hour hydrotherapy. The intervention period was nine months, and the intervention was compared to an individualised home exercise program.<BR/> <BR/>The participants in the study of <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK> were randomised into three groups: firstly an inpatient group receiving a three-week program, including one hour group exercise five days a week and, in addition, hydrotherapy three times per week; secondly, an outpatient hydrotherapy and home exercise group; and finally, a group doing individualised home exercises. The analyses in this review did not include the outpatient hydrotherapy group. Thus, the three weeks inpatient intervention program was compared to the individualised home exercise intervention. </P>
<P>
<LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK> investigated the efficacy of combined spa-exercise therapy in addition to standard treatment with drugs and weekly group physiotherapy. The spa-exercise interventions were provided in two groups, one group treated in a spa resort in Austria and one in The Netherlands. These two groups were considered clinically similar and were combined for analytical purposes in this review. The three week spa-exercise therapy consisted of group physical exercises, walking, correction therapy (lying supine), hydrotherapy, sports and sauna. A control group stayed home and followed weekly group physiotherapy sessions. After the intervention period, all patients from the three groups engaged in weekly group physiotherapy sessions for another 37-week follow-up period. </P>
<P>
<LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK> compared the effect of a six-month home-based exercise intervention package with a non-intervention control group. The intervention consisted of an exercise/information video, exercise progress chart, patient education booklet and exercise reminder stickers. </P>
<P>In the study of <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>, a group of patients was included in a six-week intensive, supervised physiotherapy program. The exercise program included stretching, mobilization and strengthening exercises, aerobic exercises and postural and respiratory exercises; this intervention was compared to an individualised home exercise program. </P>
<P>All interventions in all studies were delivered by physiotherapists. </P>
<P>
<LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK> compared two groups exposed to the climate carried out a study at the Dead Sea area; one was combined with balneotherapy and the other with access to fresh water pool.</P>
<P>In the study of <LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>, two different exercise programs were compared, an "experimental" program versus a "conventional" program, both applied for 60 minutes once a week, 15 sessions over four months. The experimental program addressed the postural affection of AS, focusing on the shortened muscle chains according to the Global Posture Reeducation method. </P>
<P>
<LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK> compared the effect of an individual 30-minute exercise program per day for eight weeks with a group of wait-list controls, and <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK> compared a group doing a multimodal supervised exercise program 50 minutes three days per week for three months with a no-intervention group. </P>
<P>
<B>Outcomes <BR/>
</B>In eight studies, pain was measured with a VAS-scale (0 to 10 cm), and in one study (<LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK>) with a self-efficacy scale (1 to 10 cm). <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK> combined the scores of pain and stiffness to produce one assessment (two VAS scales added giving a maximum score of 200); <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK> measured stiffness on a separate VAS scale (0 to 10 cm). <LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>, <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>, <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>, and <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK> reported the duration of morning stiffness in minutes; the other studies did not measure stiffness. </P>
<P>Spinal mobility was measured in eight studies. <LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>, <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>, <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK> and <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK> measured the patient's distance from fingertip to floor (FFD) in maximal flexed position (in cm). <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK> assessed the thoracolumbar flexion and extension using the 10 cm segment method (Miller) while <LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>, <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>, <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>, <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK> and <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK> used the Modified Schober's test (cm). The chest expansion was measured in cm by <LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>, <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK> and <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>, and cervical rotation was reported in degrees by <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK> and <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>. Tragus or occiput to wall and chin-to-chest distance were included in the studies of <LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>, <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK> and <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK>. </P>
<P>Physical functioning and health status were assessed by the Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S: 0 to 3, 3 worst score) and the Functional Index (FI: 0 to 2, 2 worst score) in the study of <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>. <LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>, <LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>, <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>, <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK> and <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK> measured self-reported physical functioning by the Bath Ankylosing Spondylitis Functioning Index (BASFI: VAS scales 0 to 10 cm, 10 worst score). The other studies did not include physical function. </P>
<P>Patient global assessment was reported by <LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>, <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>, <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK> and <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>. </P>
<P>Points of assessment varied in the studies. In <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>, assessment points were two times prior to intervention, immediately after completing treatment, and two, four and six months after cessation of treatment. <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK> evaluated the participants at baseline and subsequently every third month up to nine months. <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK> evaluated the patients at baseline and after the four-month intervention period; <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK> at baseline and after the six-month intervention period; and <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK> at baseline, after the six-week intervention period and at three months. In the study of <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>, the points of assessment were baseline (two weeks before spa-exercise therapy) and at one, four, seven and ten months after the start of the spa-exercise therapy. <LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK> evaluated after the three-week intervention period and after three months, <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK> only after three months, <BR/>and <LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK> after treatment and at four and 12 weeks. <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK> measured the participants after the eight-week exercise period and <LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK> published results from after treatment, six and twelve months. </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Four of the included studies met the <B>concealment of allocation criteria </B>(<LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>; <LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>; <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>; <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>). In the other studies, the randomization procedure did not meet the quality criteria or the description of the procedure was not clear. </P>
<P>
<B>Co-interventions </B>in the trials were adequately reported by <LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>, <LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>, <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>, <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK> and <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>. These studies met the criterion for avoiding performance bias, the other studies did not report if co-interventions were avoided or comparable in the groups. </P>
<P>
<B>Exclusions or losses to follow up were less than 20%</B> in seven studies (<LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>; <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>; <LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK>; <LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>; <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>; <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>; <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>). In the other studies, losses to follow up were either too large or insufficiently reported. </P>
<P>In eight of the studies, the <B>assessor was unaware of the assigned treatment </B>when collecting outcome measures (<LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>; <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>; <LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>; <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>; <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK>; <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>; <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>; <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>). The others did not meet the criterion for avoiding detection bias or were rated as unclear on this criterion. <B>Blinding of patients</B> was not met in any studies. </P>
<P>The overall assessment of the methodological quality of the trials in this review was as follows: Three studies (<LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>; <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>; <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>) met four of five criteria of internal validity and were rated to have low risk of bias. Three studies (<LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>; <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>; <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>) met three criteria and were assessed to have moderate risk of bias. Five studies met fewer than three criteria, and were assessed to have high risk of bias (<LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK>; <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>; <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK>; <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>; <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK>) (see table 'Characteristics of included studies'). </P>
<P>
<B>Baseline comparability <BR/>
</B>Even if <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK> stratified the participants into two disease severity groups before randomisation, the treatment groups varied in proportion of patients in each severity group, resulting in different baseline values. In the study of <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>, there were no relevant differences between the study groups at baseline. In the study of <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>, the initial measurements of the groups were comparable except for one variable; the control group reported significantly more rib cage pain and stiffness than the experimental group. In the study of <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK>, the groups were comparable at baseline. <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK> found the groups comparable at baseline in all parameters except for Modified Schober. In <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>, relatively more men than women were allocated to the control group than to the intervention groups; remaining characteristics were balanced among the groups.</P>
<P>In the study of <LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>, the control group reported significantly longer lasting morning stiffness, whereas the other parameters were comparable at baseline. The authors reported no significant differences in the baseline values in the study of <LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK>, <LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>, <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK> and <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>. However, although statistically comparable baseline values were reported, there was considerable imbalance for some measures. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Eleven trials with a total of 763 participants were included in this updated review, as compared to six trials and 561 participants in the previous version. Four studies compared physiotherapy interventions with no intervention (Main comparison 1) (<LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK>; <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>; <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>; <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK>). Seven studies compared different modalities or applications of physiotherapy (Main comparison 2) (<LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>; <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>; <LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK>; <LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>; <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>; <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>; <LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>). </P>
<P>
<B>Main comparison 1 - physiotherapy versus other treatment (including no treatment) </B>
<BR/>Three trials comparing home exercise and educational programs with no intervention were included (<LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>; <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>; <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK>). One of the studies was assessed to have moderate risk of bias (<LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>) and two to have high risk of bias (<LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>; <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK>). One trial, with high risk of bias, examined the effects of a 12-week, multimodal exercise program compared to no intervention (<LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK>). </P>
<P>
<B>Pain <BR/>
</B>In the study of <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>, no significant differences between the groups were found in pain reduction from baseline to four months. In the study of <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK>, a small but significant difference was found in favour of the intervention group (Weighted Mean Difference (WMD 0.56; 95% CI 0.2 to 0.9)). The relative percentage difference (RPD) was 2% (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Exact point estimates are not reported in the study of <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>, but a significant difference in favour of the exercise group was reported for VAS pain (p &lt; 0.0001). <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK> did not measure pain. Based on these results, we conclude that there is low quality of evidence for a small pain reduction in favour of the individual exercise programs compared to no intervention. </P>
<P>
<B>Stiffness <BR/>
</B>Stiffness was not measured in the studies. However, stiffness is included in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and no group differences were found on the BASDAI in the study of <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK>. <BR/>
<B>
<BR/>Spinal mobility <BR/>
</B>In the study of <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK>, spinal mobility was measured as fingertip-to-floor distance (FFD). After the four-month intervention period, the intervention group had improved significantly compared to the control group (p &lt; 0.001). The RPD was estimated at 37% in favour of the intervention group (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>), while no significant difference was found in the Schober test. <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK> reported a significant difference in favour of the exercise group in Schober test (WMD (CI)1.35 (0.14, 2.56), RPD was 5% (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). The WMD (CI) for FFD in this study was not significant (3.39 (-14.6, 7.8)), RPD 17% (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK> reported significantly more improvement on FFD for the exercise group compared to the control group (p &lt; 0.001) (insufficient data reporting for recalculation of effects). Further, <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK> reported a significant difference in favour of exercises for chest expansion (WMD(CI)1.46 (0.29,2.63), RPD 49.7% (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). Significant differences in favour of exercises were also reported for occiput to wall distance (OWD) (WMD(CI) 2.56 (4.9, 0.2) and chin to chest distance (CCD) (WMD (CI) 1.88 (3.1, 0.7), RPD 21% and 32% respectively (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK> did not measure spinal mobility. We conclude that there is moderate quality evidence for a positive effect of individual exercise programs, home-based or supervised, on some measures of spinal mobility, when compared to a no-intervention group. </P>
<P>
<B>Physical function <BR/>
</B>Physical function score was significantly better in the experimental group than in the no-intervention group in the study of <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK> (p &lt; 0.001). Average difference after treatment was about four points on a 33-point scale (modified Toronto Activities of Daily Living Questionnaire). <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK> reported no significant group difference after six months for self-reported physical function (BASFI), p = 0.08, and <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK> did not measure physical function. <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK> reported significantly larger improvement in physical function (BASFI) in the exercise group than in the control group (p &lt; 0.001). In conclusion, there is moderate quality evidence for a treatment effect on self-reported physical function when compared to no intervention. </P>
<P>
<B>Patient global assessment </B>was not measured in the studies of <LINK REF="STD-Ince-2006" TYPE="STUDY">Ince 2006</LINK>, <LINK REF="STD-Kraag-1990" TYPE="STUDY">Kraag 1990</LINK> and <LINK REF="STD-Lim-2005" TYPE="STUDY">Lim 2005</LINK>. <LINK REF="STD-Sweeney-2002" TYPE="STUDY">Sweeney 2002</LINK> reported no group differences in the Bath AS patient global score (BAS-G). Thus, there is low quality of evidence for no difference between the groups on patient global assessment. </P>
<P>
<B>Main comparison 2 - different modalities or applications of physiotherapy<BR/> </B>The following subcomparisons were made:<BR/>
<B>
<BR/>
</B>2a) Three trials comparing supervised group physiotherapy (including hydrotherapy) with home exercise regimes were included in this comparison. One trial was assessed to have low risk of bias (<LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>), one to have moderate risk (<LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>), and one to have high risk of bias (<LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>). </P>
<P>2b) One trial (low risk of bias) comparing the effectiveness of spa therapy with weekly group physiotherapy was included (<LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>). </P>
<P>2c) One trial (moderate risk of bias) comparing the effectiveness of balneotherapy and exercises with exercises alone was included (<LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>).<BR/> <BR/>2d) One trial (high risk of bias) comparing the effectiveness balneotherapy with fresh water therapy (<LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK>) was included.</P>
<P>2e) One trial (low risk of bias) comparing an experimental muscle chain exercise program with a conventional program was included (<LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>) .</P>
<P>
<B>
<I>2a) Supervised group physiotherapy (including hydrotherapy) versus home exercise regimes </I>
</B>
<I>
<BR/>
</I>
<BR/>
<I>Pain <BR/>
</I>
<LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK> found no significant differences in pain between the groups. <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK> measured pain at rest and during activity and found no significant differences between the groups after treatment or after three months. </P>
<P>
<LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK> combined pain and stiffness in one variable and found a significant difference immediately after treatment (WMD -3.90 cm (95% CI -7.7 to -0.06), RPD 48% (<LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>). However, six months after the intervention there were no significant differences between the three treatment groups regarding pain and stiffness. Thus, it is reasonable to state that there is moderate quality evidence for no difference in pain intensity between the groups. <BR/>
<B>
<BR/>
</B>
<I>Stiffness <BR/>
</I>No significant differences in stiffness were found between the groups after nine months in the study of <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>. In the study of <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>, duration of morning stiffness in minutes was measured. The authors reported statistically significant improvement after treatment and at three months follow up. However, between-group analyses showed no significant differences at the two measurement points (WMD -16.13; 95% CI -45.22 to 12.96 and -11.50; 95% CI -32.84 to 9.84, respectively). The quality of evidence for no group difference is considered to be moderate. <BR/>
<B>
<BR/>
</B>
<I>Spinal mobility <BR/>
</I>
<LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK> found a statistically significant difference for thoraco-lumbar mobility in favour of the additional group physiotherapy after the nine-month intervention period (WMD(CI) 0.4 cm (0.1,0.7), RPD 7.5% in favour of the supervised group physiotherapy. This group also performed slightly better on the other spinal mobility outcomes, but the results were not statistically significant. Chest expansion and Schober test were measured after treatment in two studies (<LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>; <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>) and pooled analyses showed no significant differences between the groups for these two measures. A significant difference in Schober test was found between the groups at three months in the study of <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK> with an absolute benefit of 0.6 cm and RPD 18% (<LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>). Furthermore, no difference in cervical rotation between the supervised group program and the home exercise group, after treatment or six months after treatment, was found in the study of <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>. In the study of <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK>, no difference between the groups was found on FFD or tragus to wall distance (TWD). In conclusion, the quality of evidence for small beneficial effects on some measures of spinal mobility in favour of group physiotherapy is considered to be moderate.<BR/> <BR/>
<I>Physical function <BR/>
</I>
<LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK> and <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK> found no significant differences in self-reported physical function measured at nine and three months respectively. The quality of evidence for no group differences is moderate. <BR/>
<B>
<BR/>
</B>
<I>Patient global assessment <BR/>
</I>The supervised group reported significantly better scores on the patient global assessment in the study of <LINK REF="STD-Hidding-1993" TYPE="STUDY">Hidding 1993</LINK>. Mean change difference between the two groups after the nine-month intervention period was 1.46 cm (CI 95% 1.05 to 1.87); RPD was not calculated due to insufficient reporting of baseline data. Patient global assessment was not measured in the studies of <LINK REF="STD-Analay-2003" TYPE="STUDY">Analay 2003</LINK> and <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK>. The quality of evidence for a difference in favour of group physiotherapy is considered to be moderate. </P>
<P>
<B>
<I>2 b) Spa therapy and group physiotherapy versus group physiotherapy alone</I>
</B>
<I>
<BR/>
</I>
<BR/>One study with low risk of bias was included (<LINK REF="STD-Van-Tubergen-2001" TYPE="STUDY">Van Tubergen 2001</LINK>). The two spa-exercise groups were considered clinically similar and thus they were combined to perform one group (intervention group: IG) which was compared to weekly group physiotherapy alone (control group: CG). The authors expressed the primary outcomes (BASFI, BAS-G, pain intensity and morning stiffness) as a pooled index of change (PIC). Both the pooled index and the individual variables were reported. <BR/>
<B>
<BR/>
</B>
<I>Pain <BR/>
</I>Significant effects of the spa-exercise intervention were found regarding pain. At one month WMD was -1.07 (CI 95% -2.02 to -0.12), and at four months WMD was -1.09 (CI 95% -2.04 to -0.14). Absolute benefit at one and four months was 0.9 cm and RPD 18% in favour of the spa-exercise group (<LINK REF="TBL-11" TYPE="TABLE">Table 11</LINK>). After seven months, the authors still reported a significant difference between the IG and the CG on a pooled index (PIC). However, no significant differences in pain were found at seven or 10 months when regarded as an individual variable. It may be reasonable to conclude that there is moderate quality evidence for a clinically relevant effect of the spa-exercise intervention on pain. <BR/>
<B>
<BR/>
</B>
<I>Stiffness <BR/>
</I>Stiffness was measured as duration of morning stiffness, in minutes. Significant differences between the spa-exercise groups and the control group were not found. Thus, the quality of evidence for no group differences is moderate. <BR/>
<B>
<BR/>
</B>
<I>Spinal mobility <BR/>
</I>Spinal mobility was not measured in this study. <BR/>
<B>
<BR/>
</B>
<I>Physical function <BR/>
</I>Physical function was measured with BASFI and included in the pooled index of change. Evaluated as a separate variable there was no statistically significant difference between the groups, but the RPD was 24% and 17% at one and four months respectively (<LINK REF="TBL-12" TYPE="TABLE">Table 12</LINK>). The quality of evidence for no group differences is moderate. <BR/>
<B>
<BR/>
</B>
<I>Patient global assessment <BR/>
</I>Significant positive effects of the spa-exercise interventions were found for patient global assessment at one month (WMD -0.93; 95% CI -1.78 to -0.09), four months (WMD -0.93; 95% CI -1.84 to -0.02) and seven months (WMD -1.00; CI -2.02 to 0.02). The absolute benefit was 1.3 cm, 1.4 cm and 1.4 cm respectively; the RPD, in favour of the spa-exercise groups, was 27% at one month and 29% at four and seven months (<LINK REF="TBL-13" TYPE="TABLE">Table 13</LINK>). At 10 months, no differences between the groups were found. There is moderate quality evidence for a clinically relevant effect in favour of an additional combined spa-exercises course.</P>
<P>
<B>
<I>2c) Balneotherapy and exercises versus exercises alone<BR/>
</I>
</B>
<BR/>One study with moderate risk of bias was included (<LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK>).<BR/>
<B>
<BR/>
</B>
<I>Pain<BR/>
</I>No group differences were found for day or night pain, and RPDs of less than 10% were found in all assessment points (<LINK REF="TBL-15" TYPE="TABLE">Table 15</LINK>). We concluded that there is low quality evidence for no group differences in pain. <BR/>
<B>
<BR/>
</B>
<I>Stiffness<BR/>
</I>
<LINK REF="STD-Altan-2006" TYPE="STUDY">Altan 2006</LINK> reported morning stiffness on a 0-3 point scale. No significant group differences were found after treatment or at 24 weeks, thus there is low quality evidence for no group differences regarding morning stiffness.<BR/>
<B>
<BR/>
</B>
<I>Spinal mobility<BR/>
</I>Schober test, FFD, OWD and chest expansion were measured and no significant group differences were found. Thus, we conclude that there is low quality evidence for no effect on spinal mobility. <BR/>
<B>
<BR/>
</B>
<I>Physical function<BR/>
</I>After treatment, the WMD for BASFI was 0.11(ns). The RPDs after treatment and at 24 weeks were 53% and 58%. However, considerable differences in baseline scores might have inflated the RPDs (<LINK REF="TBL-19" TYPE="TABLE">Table 19</LINK>). Conclusively, there is low quality evidence for no effect on BASFI.<BR/>
<B>
<BR/>
</B>
<I>Patient global assessment<BR/>
</I>Small, not significant WMDs were found for patients' global evaluation after treatment and at 24 weeks. However, the RPD was 21% after treatment, indicating a possible clinical relevant after treatment effect on this variable (<LINK REF="TBL-17" TYPE="TABLE">Table 17</LINK>). Conclusively, low quality evidence for no effect.</P>
<P>
<B>
<I>2d) Balneotherapy versus fresh water therapy</I>
</B>
<I>
<BR/>
</I>
<BR/>One study with high risk of bias<B> </B>(<LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK>) was included. <BR/>
<B>
<BR/>
</B>
<I>Pain<BR/>
</I>No significant group differences on pain were reported at any assessment point, thus there is low quality evidence for no effect <BR/>
<B>
<BR/>
</B>
<I>Stiffness<BR/>
</I>Morning stiffness in minutes was reported as a baseline characteristic, but no after treatment results were reported. BASDAI was also included, but did not show group differences, thus there is low quality evidence for no effect.<BR/>
<B>
<BR/>
</B>
<I>Spinal mobility<BR/>
</I>
<LINK REF="STD-Codish-2005" TYPE="STUDY">Codish 2005</LINK> reported limitation of movement on a VAS scale. No significant WMDs were found, but RPDs 22% (after treatment) and 18% (four and 12 weeks) were calculated (<LINK REF="TBL-22" TYPE="TABLE">Table 22</LINK>). We conclude that there is low quality evidence for no group differences regarding mobility. </P>
<P>
<B>Physical function</B> and <B>Patient global assessment</B> were not reported</P>
<P>
<B>
<I>2e) An experimental exercise program versus a conventional program</I>
</B>
<I>
<BR/>
</I>
<BR/>One study with low risk of bias (<LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK>) was included. <BR/>
<B>
<BR/>
</B>
<I>Pain<BR/>
</I>
<LINK REF="STD-D_x0027_Las-Pe_x00f1_as-2005" TYPE="STUDY">D'Las Peñas 2005</LINK> did not include a separate pain measure; BASDAI was used, but no group differences were found at any assessment point.</P>
<P>
<B>Stiffness </B>was not measured <BR/>
<B>
<BR/>
</B>
<I>Spinal mobility<BR/>
</I>The elements of BASMI (Schober test, lumbar side flexion, intermalleolar distance, cervical rotation, TWD) were measured, and no significant group differences were found after treatment or at one year follow up. Some clinical relevant differences were calculated (<LINK REF="TBL-24" TYPE="TABLE">Table 24</LINK>), and a comparison of the prepost scores between the two groups shows that the experimental group improved significantly more than the control group in all spinal mobility measures except TWD. We conclude that there is moderate quality evidence for group differences in favour of the experimental exercise group. </P>
<P>
<I>Physical function<BR/>
</I>There was no significant WMD for BASFI at any assessment point. However, an intergroup comparison between the improvement (prepost change scores) showed that the experimental group improved significantly more, and we conclude that there is moderate quality evidence for beneficial effect on BASFI in favour of the experimental exercise program compared to the conventional program. <BR/>
<B>
<BR/>Patient global assessment </B>was not measured.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Eleven studies met the inclusion criteria of this review, with a total of 763 patients with AS. Three of the studies were assessed to have low risk of bias, three studies were assessed to have moderate, and five to have high risk of bias. We can conclude from this review that patients with AS have some beneficial effects from individualised home exercise programs compared to no intervention. Furthermore, supervised group physiotherapy programs are slightly better than individualised home exercise regimes, and a three-week combined spa-exercise intervention is better than weekly group physiotherapy alone. An experimental chain muscle exercise program showed larger improvement than a conventional exercise program. For the remaining studies comparing different modalities/programs or applications of physiotherapy, improvements were found for all programs from baseline to after treatment, but no between-group differences were reported. </P>
<P>Most of the studies in this review included more than 70% men. Since AS seems to affect men and women differently (<LINK REF="REF-Dagfinrud-2005" TYPE="REFERENCE">Dagfinrud 2005</LINK>; <LINK REF="REF-Lee-2007" TYPE="REFERENCE">Lee 2007</LINK>), it is important to underline that the applicability of the results to women may be limited. Further, the exclusion criteria in the studies included use of DMARDs, patients with peripheral joint involvement, severe co-morbidity and diagnosis of AS more than 20 years ago. Thus, the applicability to severely affected AS patients may also be limited.</P>
<P>The main goal of the trials in this review was to study the effectiveness of physiotherapy in the management of AS. However, interventions are often poorly described, different types of exercises and training doses are used and the expected physiological responses to the exercise programs are not defined. Consequently, the optimal exercise program for patients with AS can still not be determined. Another problem related to the external validity is the use of unavailable interventions, such as treatment programs in spa resorts or at the Dead Sea area. Although spa-exercise interventions have shown favourable cost-effectiveness and cost-utility ratios compared to self-exercising and group exercising (<LINK REF="STD-Van-Tubergen-2002" TYPE="STUDY">Van Tubergen 2002</LINK>), spa resorts and Dead Sea climate are not easily available in many parts of the world and the generalisability of the results may therefore be limited. <B>
<BR/>
</B>
<BR/>In order to improve the clinical relevance of the review, relative percentage differences (RPD) were calculated when possible. According to the <LINK REF="REF-Philadelphia-Panel" TYPE="REFERENCE">Philadelphia Panel</LINK>, an improvement of 15% relative to a control group can be considered as clinically relevant (<LINK REF="REF-Philadelphia-Panel" TYPE="REFERENCE">Philadelphia Panel</LINK>). For several outcomes, clinically relevant differences were found, even if they were not statistically significant. However, the calculation of RPD is based on the difference between the change scores in the two groups, but the variation (standard deviation) of the scores is not taken into consideration, and the RPD must therefore be interpreted with caution, especially in underpowered studies. Further, small sample sizes often result in baseline incomparability, which also complicate correct estimation of benefit. </P>
<P>We employed a systematic and explicit method to indicate the extent to which one can be confident that the effect estimates were correct (<LINK REF="REF-Grade-Working-Group" TYPE="REFERENCE">Grade Working Group</LINK>); assessments of the quality of evidence were done for each comparison and outcome. By considering study design, study quality, similarity of estimates of effect across studies and directness (the extent to which people, interventions and outcome measures are similar to those of interest) we found that the quality of evidence for the comparisons in this review was either moderate or low. Thus, further research is recommended to confirm these effect estimates.</P>
<P>Some of the trials compared therapeutic exercises applied in group settings to exercises performed individually. Thus, the comparisons may provide information on the effect of the group setting rather than the effect of the specific content of the exercise programs. The fact that the patients who participated in groups improved more than the patients who did exercises on their own may be ascribed to the contribution of non-physical factors, such as mutual encouragement, increased motivation and exchange of experiences with fellow sufferers. These are important factors for the total well-being, but do not give evidence to decide the most appropriate and effective exercise program. </P>
<P>Although the RCT is considered to be the best design, the random allocation of patients may lead to reduced effectiveness of the interventions in physiotherapy studies. Physiotherapy interventions are often time consuming and compliance is dependent on motivated patients. <LINK REF="STD-Helliwell-1996" TYPE="STUDY">Helliwell 1996</LINK> addressed this problem, considering that the great number of drop-outs in their study may have been due to lack of motivation and a time-consuming treatment program which the patients had not chosen. Further, when using intention-to-treat analyses, the non-compliers may influence the treatment effects negatively. Due to these challenges, researchers tend to compare active and quite similar interventions in order to avoid poor recruitment or non-compliance. In this review, comparing different modalities or applications of exercise programs resulted in improvement for both groups, but between-group differences could not be proved. Comparing two active and similar interventions diminish the contrast between them, thus, the 11 included RCTs with more than 700 patients give a disproportionately small amount of new knowledge on the effectiveness of physiotherapy interventions for AS. </P>
<P>The effects of exercises are determined by mode, frequency, intensity, duration and, not least, adherence to the program (<LINK REF="REF-Herbert-2005" TYPE="REFERENCE">Herbert 2005</LINK>). In order to contribute with new knowledge, future trials should report more thoroughly on these issues. </P>
<P>The recently published evidence-based recommendations for the management of AS conclude that optimal management requires a combination of non-pharmacological and pharmacological treatments, and that the non-pharmacological treatment should include patient education and regular exercise (<LINK REF="REF-Zochling-2006" TYPE="REFERENCE">Zochling 2006</LINK>). This statements are reinforced in a study of experts' beliefs, where physiotherapy is considered to be indicated for early AS (by 88% of the experts) and for AS of longer duration (by 94% of the experts), implying that physiotherapy should be prescribed to AS patients (<LINK REF="REF-Mihai-2005" TYPE="REFERENCE">Mihai 2005</LINK>). Thus, even if the evidence base for exercises as shown in the present review is relatively weak, there seems to be agreement among clinicians and experts that exercises is a cornerstone in the management of AS. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The results of this review give low quality evidence for beneficial effects of exercise program compared to no intervention, and moderate evidence for benefits of supervised group physiotherapy compared to individualised home programs. A combined spa-exercise and group physiotherapy program was more effective than only group physiotherapy in the management of AS, and an experimental muscle chain exercise program might be better than conventional exercises. However, it must be emphasised that small numbers of participants, heterogeneous interventions and outcome measures, together with deficient reporting of data in these studies do not provide strong evidence. </P>
<P>No randomised trials investigating relevant physiotherapy interventions other than exercise programs were found through this systematic search strategy. To improve practice and decision making, it is important to conduct trials examining different modes, frequency, intensity, duration and adherence of the exercise programs. Further, trials investigating other commonly used physiotherapy approaches such as different hands-on techniques and specific education and information programs are still lacking. Accordingly, we still do not know which particular treatment protocol to be recommended in the management of AS. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>More trials are needed in this field. Other commonly used physiotherapy interventions (e.g. different hands-on techniques such as manual therapy, electrotherapy, information and education programs) should be investigated. New trials should compare different treatment and exercise programs and aspire to provide an accurate description of the content, dose, application and adherence to the interventions. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Louise Falzon at the editorial office of the Cochrane Musculoskeletal Group conducted the literature searches for this updated version. The authors of the primary studies are acknowledged for their cooperation. Opinions and interpretations expressed in this review do not necessarily represent those of the institutions with which the authors are affiliated.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>HD planned and initiated the review, searched for RCTs, assessed the trials, extracted data, contacted authors of RCTs and drafted and redrafted the update of the review. KBH planned and initiated the review, contacted authors of RCTs and assessed the trials and extracted data. TKK contributed substantially in the updating process with comments and interpretation of the data. HD is the guarantor for the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-Altan-2006" NAME="Altan 2006" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altan L, Bingol U, Aslan M, Yurtkuran M</AU>
<TI>The effect of balneotherapy on patients with ankylosing spondylitis</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>2006</YR>
<VL>35</VL>
<PG>283-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Analay-2003" NAME="Analay 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Analay Y, Ozcan E, Karan A, Diracoglu D, Aydin R. The effectiveness of intensive group exercise on patients with ankylosing spondylitis. Clin Rehabil 2003; 17(6):631-636.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Analay Y, Ozcan E, Karan A, Diracoglu D, Aydin R</AU>
<TI>The effectiveness of intensive group exercise on patients with ankylosing spondylitis</TI>
<SO>Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>6</NO>
<PG>631-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Codish-2005" NAME="Codish 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Codish S, Dobrovinsky S, Abu SM, Flusser D, Sukenik S</AU>
<TI>Spa therapy for ankylosing spondylltis at the Dead Sea</TI>
<SO>The Israel Medical Association Journal</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>443-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-D_x0027_Las-Pe_x00f1_as-2005" NAME="D'Las Peñas 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez-de-Las-Penas C, Alonso-Blanco C et al.</AU>
<TI>Middle term follow-up physical function improvement after rehabilitation treatment by working the muscle chain in ankylosing spondylitis</TI>
<TO>Seguimiento a medio plazo de la mejora fifica y funcional tras tratamiento rehabilitador mediante el trabajo de cadenas musculares en la espondilitis anquilosante</TO>
<SO>Rehabilitacion</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>5</NO>
<PG>222-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez-de-Las-Penas C, Alonso-Blanco C, Alquacil-Diego IM, Miangolorra-Page JC</AU>
<TI>One-year follow-up of two exercise interventions for the management of patients with ankylosing spondylitis: a randomized controlled trial</TI>
<SO>American Journal of Physical Medicine and Rehabilitation</SO>
<YR>2006</YR>
<VL>85</VL>
<NO>7</NO>
<PG>559-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez-de-Las-Penas C, Alonso-Blanco C, Morales-Cabezas M, Miangolorra-Page JC</AU>
<TI>Two exercise interventions for the management of patients with ankylosing spondylitis: a randomized controlled trial</TI>
<SO>American Journal of Physical Medicine and Rehabilitation</SO>
<YR>2005</YR>
<VL>84</VL>
<PG>407-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Helliwell-1996" NAME="Helliwell 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Helliwell P, Abbott CA, Chamberlain MA</AU>
<TI>A randomised trial of three different physiotherapy regimes in ankylosing spondylitis</TI>
<SO>Physiotherapy 1996</SO>
<VL>82</VL>
<NO>2</NO>
<PG>85-90</PG>
<EN>82</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hidding-1993" NAME="Hidding 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hidding A, van der Linden S, Boers M, Gielen X, de Witte L, Kester A, et al</AU>
<TI>Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial</TI>
<SO>Arthritis Care and Research</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>3</NO>
<PG>117-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ince-2006" NAME="Ince 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ince G, Sarpel T, Durgun B, Erdogan S</AU>
<TI>Effects of a multimodal exercise program for people with ankylosing spondylitis</TI>
<SO>Physical Therapy</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>7</NO>
<PG>924-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraag-1990" NAME="Kraag 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kraag G, Stokes B, Groh J, Helewa A, Goldsmith C</AU>
<TI>The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis--a randomized controlled trial</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1990</YR>
<VL>17</VL>
<NO>2</NO>
<PG>228-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lim-2005" NAME="Lim 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lim H-J, Moon Y-I, Lee MS</AU>
<TI>Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis</TI>
<SO>Rheumatol International</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>3</NO>
<PG>225-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sweeney-2002" NAME="Sweeney 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Sweeney S, Taylor G, Calin A. The effect of a home based exercise intervention package on outcome in ankylosing spondylitis: a randomized controlled trial. J Rheumatol 2002; 29(4):763-766.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sweeney S, Taylor G, Calin A</AU>
<TI>The effect of a home based exercise intervention package on outcome in ankylosing spondylitis: a randomized controlled trial</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>4</NO>
<PG>763-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Van-Tubergen-2001" NAME="Van Tubergen 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Van Tubergen A, Landewe R, van der HD, Hidding A, Wolter N, Asscher M et al. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001; 45(5):430-438.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Tubergen A, Landewe R, van der HD, Hidding A, Wolter N, Asscher M et al</AU>
<TI>Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2001</YR>
<VL>45</VL>
<NO>5</NO>
<PG>430-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Ammer-1997" NAME="Ammer 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Ammer K. Physiotherapy in Seronegative Spondylarthropathies. A systematic review. European journal of physical rehabilitation 1997; 4:114-119.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ammer K</AU>
<TI>Physiotherapy in seronegative spondylarthropathies. A systematic review</TI>
<SO>European Journal of Physical Rehabilitation</SO>
<YR>1997</YR>
<VL>4</VL>
<PG>114-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Backlund_x002c_-1998" NAME="Backlund, 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Backlund M, Lundmark H, Niklasson K, Sundelin G</AU>
<TO>Förändringar i ryggradens rörlighet hos patienter me Bechterews sjukdom-en femårsuppföljning</TO>
<SO>Nordisk Fysioterapi 1998</SO>
<VL>2</VL>
<PG>67-72</PG>
<EN>2</EN>
<PB>Scandinavian University Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bakker-et-al-1994" NAME="Bakker et al 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bakker C, Hidding A, van der Linden S, van Doorslaer E</AU>
<TI>Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis. A randomized controlled trial</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1994</YR>
<VL>21</VL>
<NO>2</NO>
<PG>264-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Band-1997" NAME="Band 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Band DA, Jones SD, Kennedy LG, Garrett SL, Porter J, Gay L, et al</AU>
<TI>Which patients with ankylosing spondylitis derive most benefit from an inpatient management program?</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>12</NO>
<PG>2381-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bender-2005" NAME="Bender 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bender T, Karagülle Z, Bálint G, Gutenbrunner C, Bálint PV, Sukenik S</AU>
<TI>Hydrotherapy, balneotherapy, and spa treatment in pain management</TI>
<SO>Rheumatol International</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>3</NO>
<PG>220-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bulstrode-1986" NAME="Bulstrode 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bulstrode SJ, Barefoot J, Harrison RA, Clarke AK</AU>
<TI>The role of passive stretching in the treatment of ankylosing spondylitis</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1987</YR>
<VL>26</VL>
<NO>1</NO>
<PG>40-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Las-Pe_x00f1_as-c2005" NAME="D'Las Peñas c2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez-de-Las-Penas C, Alonso-Blanco C et al.</AU>
<TI>Middle term follow-up physical function improvement after rehabilitation treatment by working the muscle chain in ankylosing spondylitis</TI>
<TO>Seguimiento a medio plazo de la mejora fifica y funcional tras tratamiento rehabilitador mediante el trabajo de cadenas musculares en la espondilitis anquilosante</TO>
<SO>Rehabilitacion</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>5</NO>
<PG>222-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falkenbach-2003" NAME="Falkenbach 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Falkenbach A. Disability motivates patients with ankylosing spondylitis for more frequent physical exercise. Archives of Physical Medicine and Rehabilitation 2003; 84(3):382-383.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falkenbach A</AU>
<TI>Disability motivates patients with ankylosing spondylitis for more frequent physical exercise</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>2003</YR>
<VL>84</VL>
<NO>3</NO>
<PG>382-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisher-1990" NAME="Fisher 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fisher LR, Cawley MI, Holgate ST</AU>
<TI>Relation between chest expansion, pulmonary function, and exercise tolerance in patients with ankylosing spondylitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1990</YR>
<VL>49</VL>
<NO>11</NO>
<PG>921-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gall-1994" NAME="Gall 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gall V</AU>
<TI>Exercise in the spondyloarthropathies</TI>
<SO>Arthritis Care and Research</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>4</NO>
<PG>215-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hafstrom-2003" NAME="Hafstrom 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Hafstrom I, Hallengren M. Physiotherapy in subtropic climate improves functional capacity and health-related quality of life in Swedish patients with rheumatoid arthritis and spondylarthropathies still after 6 months. Scand J Rheumatol 2003; 32(2):108-113.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hafstrom I, Hallengren M</AU>
<TI>Physiotherapy in subtropic climate improves functional capacity and health-related quality of life in Swedish patients with rheumatoid arthritis and spondylarthropathies still after 6 months</TI>
<SO>Scandanavian Journal of Rheumatology</SO>
<YR>2003</YR>
<VL>32</VL>
<NO>2</NO>
<PG>108-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heikkila-2000" NAME="Heikkila 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Heikkila S, Viitanen JV, Kautiainen H, Kauppi M. Sensitivity to change of mobility tests; effect of short term intensive physiotherapy and exercise on spinal, hip, and shoulder measurements in spondyloarthropathy. J Rheumatol 2000; 27(5):1251-1256.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heikkila S, Viitanen JV, Kautiainen H, Kauppi M</AU>
<TI>Sensitivity to change of mobility tests; effect of short term intensive physiotherapy and exercise on spinal, hip, and shoulder measurements in spondyloarthropathy</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>5</NO>
<PG>1251-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hidding-1994" NAME="Hidding 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Hidding A., van der Linden, S., Gielen, X., de Witte, L., Dijkmans, B., Moolenburgh, D.. &amp;quot;Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial&amp;quot;. Arthritis Care Res 1994; 7(2): 90-96.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hidding A, van der Linden S, Gielen X, de Witte L, Dijkmans B, Moolenburgh D</AU>
<TI>Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial</TI>
<SO>Arthritis Care and Research</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>2</NO>
<PG>90-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hidding-1995" NAME="Hidding 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hidding A, van der LS</AU>
<TI>Factors related to change in global health after group physical therapy in ankylosing spondylitis</TI>
<SO>Clinical Rheumatology</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>3</NO>
<PG>347-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hider-2002" NAME="Hider 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Hider S, Wong M, Ortiz M, Dulku A, Mulherin D. Does a regular exercise program for ankylosing spondylitis influence body image? Scand J Rheumatol 2002; 31(3):168-171.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hider S, Wong M, Ortiz M, Dulku A, Mulherin D</AU>
<TI>Does a regular exercise program for ankylosing spondylitis influence body image?</TI>
<SO>Scandanavian Journal of Rheumatology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>3</NO>
<PG>168-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horslev_x002d_Petersen1985" NAME="Horslev-Petersen1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Horslev-Petersen K, Rasmussen JO, Helin P. [Continuing training of patients with advanced ankylosing spondylitis]. Ugeskr Laeger 1985;147(2):99-101.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Horslev-Petersen K, Rasmussen JO, Helin P</AU>
<TI>[Continuing training of patients with advanced ankylosing spondylitis]</TI>
<SO>Ugeskr Laeger</SO>
<YR>7-1-1985</YR>
<VL>147</VL>
<NO>2</NO>
<PG>99-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraag-1994" NAME="Kraag 1994" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Kraag, G., Stokes, B.,Groh, J., Helewa, A., Goldsmith, C.H.. &amp;quot;The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis - an 8 months followup&amp;quot;. J. Rheumatol 1994; 21(2):261-263.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kraag G, Stokes B, Groh J, Helewa A, Goldsmith CH</AU>
<TI>The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis - an 8-month followup</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1994</YR>
<VL>21</VL>
<NO>2</NO>
<PG>261-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Driscoll-1978" NAME="O'Driscoll 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>O'Driscoll SL, Jayson MI, Baddeley H</AU>
<TI>Neck movements in ankylosing spondylitis and their responses to physiotherapy</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1978</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-1989" NAME="Rasmussen 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen JO, Hansen TM</AU>
<TI>Physical training for patients with ankylosing spondylitis</TI>
<SO>Arthritis Care and Research</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>1</NO>
<PG>25-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russell-1992" NAME="Russell 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Russell P, Unsworth A, Haslock I</AU>
<TI>The effect of exercise on ankylosing spondylitis--a preliminary study</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1993</YR>
<VL>32</VL>
<NO>6</NO>
<PG>498-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santos-1998" NAME="Santos 1998" YEAR="198">
<REFERENCE NOTES="&lt;p&gt;Santos H, Brophy S, Calin A. Exercise in ankylosing spondylitis: how much is optimum? J Rheumatol 1998;25(11):2156-60&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Santos H, Brophy S, Calin A</AU>
<TI>Exercise in ankylosing spondylitis: how much is optimum?</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seckin-2000" NAME="Seckin 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Seckin U, Bolukbasi N, Gursel G, Eroz S, Sepici V, Ekim N. Relationship between pulmonary function and exercise tolerance in patients with ankylosing spondylitis. Clin Exp Rheumatol 2000; 18(4):503-506.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seckin U, Bolukbasi N, Gursel G, Eroz S, Sepici V, Ekim N</AU>
<TI>Relationship between pulmonary function and exercise tolerance in patients with ankylosing spondylitis</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>4</NO>
<PG>503-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stenstrom-1997" NAME="Stenstrom 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Stenstrom CH, Arge B, Sundbom A. Home exercise and compliance in inflammatory rheumatic diseases--a prospective clinical trial. J Rheumatol 1997; 24(3):470-476.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stenstrom CH, Arge B, Sundbom A</AU>
<TI>Home exercise and compliance in inflammatory rheumatic diseases--a prospective clinical trial</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>3</NO>
<PG>470-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sundstrom-2002" NAME="Sundstrom 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Sundstrom B, Ekergard H, Sundelin G. Exercise habits among patients with ankylosing spondylitis. A questionnaire based survey in the County of Vasterbotten, Sweden.PG -. Scand J Rheumatol 2002; 31(3).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sundstrom B, Ekergard H, Sundelin G</AU>
<TI>Exercise habits among patients with ankylosing spondylitis. A questionnaire based survey in the County of Vasterbotten, Sweden.PG -</TI>
<SO>Scandanavian Journal of Rheumatology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tegelberg-1988" NAME="Tegelberg 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Tegelberg A, Kopp S. Short-term effect of physical training on temporomandibular joint disorder in individuals with rheumatoid arthritis and ankylosing spondylitis. Acta Odontol Scand 1988; 46(1):49-56.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tegelberg A, Kopp S</AU>
<TI>Short-term effect of physical training on temporomandibular joint disorder in individuals with rheumatoid arthritis and ankylosing spondylitis</TI>
<SO>Acta Odontologica Scandinavica</SO>
<YR>1988</YR>
<VL>46</VL>
<NO>1</NO>
<PG>49-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tegelberg-1996" NAME="Tegelberg 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Tegelberg A, Kopp S. A 3-year follow-up of temporomandibular disorders in rheumatoid arthritis and ankylosing spondylitis. Acta Odontol Scand 1996; 54(1):14-18.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tegelberg A, Kopp S</AU>
<TI>A 3-year follow-up of temporomandibular disorders in rheumatoid arthritis and ankylosing spondylitis</TI>
<SO>Acta Odontologica Scandinavica</SO>
<YR>1996</YR>
<VL>54</VL>
<NO>1</NO>
<PG>14-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tishler-1995" NAME="Tishler 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Tishler M, Brostovski Y, Yaron M. Effect of spa therapy in Tiberias on patients with ankylosing spondylitis. Clin Rheumatol 1995; 14(1):21-25.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tishler M, Brostovski Y, Yaron M</AU>
<TI>Effect of spa therapy in Tiberias on patients with ankylosing spondylitis</TI>
<SO>Clinical Rheumatology</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>1</NO>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomlinson-1986" NAME="Tomlinson 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Tomlinson M J, Barefoot J, Dixon A S</AU>
<TI>Intensive in-patient physiotherapy courses improve movement and posture in ankylosing spondylitis</TI>
<SO>Physiotherapy</SO>
<YR>1986</YR>
<VL>72</VL>
<NO>5</NO>
<PG>238-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uhrin-2000" NAME="Uhrin 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Uhrin Z, Kuzis S, Ward MM. Exercise and changes in health status in patients with ankylosing spondylitis. Arch Intern Med 2000; 160(19):2969-2975.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uhrin Z, Kuzis S, Ward MM</AU>
<TI>Exercise and changes in health status in patients with ankylosing spondylitis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>19</NO>
<PG>2969-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Tubergen-2002" NAME="Van Tubergen 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;van Tubergen A, Boonen A, Landewe R, Rutten-van Molken M, van der HD, Hidding A et al. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2002; 47(5):459-467.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Tubergen A, Boonen A, Landewe R, Rutten-van Molken M, van der HD, Hidding A, et al</AU>
<TI>Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>5</NO>
<PG>459-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Tubergen-2002-b" NAME="Van Tubergen 2002 b" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Van Tubergen A, Hidding A. Spa and exercise treatment in ankylosing spondylitis: fact or fancy? Best Pract Res Clin Rheumatol 2002; 16(4):653-666.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Tubergen A, Hidding A</AU>
<TI>Spa and exercise treatment in ankylosing spondylitis: fact or fancy?</TI>
<SO>Best Practice and Research Clinical Rheumatology</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>4</NO>
<PG>653-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Viitanen-1992" NAME="Viitanen 1992" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Viitanen JV, Suni J, Kautiainen H, Liimatainen M, Takala H</AU>
<TI>Effect of physiotherapy on spinal mobility in ankylosing spondylitis</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>1</NO>
<PG>38-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Viitanen-1995" NAME="Viitanen 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Viitanen JV, Lehtinen K, Suni J, Kautiainen H</AU>
<TI>Fifteen months' follow-up of intensive inpatient physiotherapy and exercise in ankylosing spondylitis</TI>
<SO>Clinical Rheumatology</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>4</NO>
<PG>413-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Viitanen-2001" NAME="Viitanen 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Viitanen JV, Heikkila S. Functional changes in patients with spondylarthropathy. A controlled trial of the effects of short-term rehabilitation and 3-year follow-up. Rheumatol Int 2001; 20(5):211-214.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Viitanen JV, Heikkila S</AU>
<TI>Functional changes in patients with spondylarthropathy. A controlled trial of the effects of short-term rehabilitation and 3-year follow-up</TI>
<SO>Rheumatology International</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>5</NO>
<PG>211-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wordsworth-1983" NAME="Wordsworth 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wordsworth BP, Pearcy MJ, Mowat AG</AU>
<TI>In-patient regime for the treatment of ankylosing spondylitis: an appraisal of improvement in spinal mobility and the effects of corticotrophin</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1984</YR>
<VL>23</VL>
<NO>1</NO>
<PG>39-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yurtukan-M" NAME="Yurtukan M" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yurtukan M, Ay A, Karakoc Y</AU>
<TI>Improvement of the clinical outcome in Ankylosing Spondylitis by balneotherapy</TI>
<SO>Joint Bone Spine</SO>
<YR>2005</YR>
<VL>72</VL>
<PG>303-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmad-2000" NAME="Ahmad 2000" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Ahmad N. A randomised comparison of intensive versus less intensive exercise for ankylosing spondylitis and the spondylarthropathies. Australian &amp;amp; New Zealand Journal of Medicine 30[4], 536. 2000.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahmad N</AU>
<TI>A randomised comparison of intensive versus less intensive exercise for ankylosing spondylitis and the spondylarthropathies.</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<VL>30</VL>
<NO>4</NO>
<PG>536</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pickering-2000" NAME="Pickering 2000" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Pickering K. Two arm clinical trial evaluating exercise in ankylosing spondylitis with a metrology index as the primary outcome variable. Australian &amp;amp; New Zealand Journal of Medicine 30[4], 548. 2000.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pickering K</AU>
<TI>Two arm clinical trial evaluating exercise in ankylosing spondylitis with a metrology index as the primary outcome variable.</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<VL>30</VL>
<NO>4</NO>
<PG>548</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Alderson-2004" NAME="Alderson 2004" NOTES="&lt;p&gt;Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers' Handbook 4.2.1. (updated December 2003). In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp;amp; Sons, Ltd.&lt;/p&gt;" TYPE="BOOK">
<AU>Alderson P, Green S, Higgins JPT, editors</AU>
<SO>Cochrane Reviewers' Handbook 4.2.1 (updated December 2003)</SO>
<PB>In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp; Sons, Ltd.</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Amor-1991" NAME="Amor 1991" NOTES="&lt;p&gt;Amor B, Dougados M, Listrat V, Menkes CJ, Dubost JJ, Roux H et al. [Evaluation of the Amor criteria for spondylarthropathies and European Spondylarthropathy Study Group (ESSG). A cross-sectional analysis of 2,228 patients]. Ann Med Interne (Paris) 1991; 142(2):85-89.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Amor B, Dougados M, Listrat V, Menkes CJ, Dubost JJ, Roux H et al</AU>
<TI>[Evaluation of the Amor criteria for spondylarthropathies and European Spondylarthropathy Study Group (ESSG). A cross-sectional analysis of 2,228 patients]</TI>
<SO>Annales de Medecine Interne (Paris)</SO>
<YR>1991</YR>
<VL>142</VL>
<NO>2</NO>
<PG>85-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Las-Pe_x00f1_as-b2005" NAME="D'Las Peñas b2005" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez-de-Las-Penas C, Alonso-Blanco C, Alguacil-Diego IM, Miangolorra-Page JC D</AU>
<TI>One-year follow-up of two exercise interventions for the management of patients with ankylosing spondylitis</TI>
<SO>American Journal of Physical Medicine and Rehabilitation</SO>
<YR>2006</YR>
<VL>85</VL>
<NO>7</NO>
<PG>559-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dagfinrud-2005" NAME="Dagfinrud 2005" TYPE="JOURNAL_ARTICLE">
<AU>Dagfinrud H, Kjeken I, Mowinckel P, Hagen KB, Kvien TK</AU>
<TI>Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>3</NO>
<PG>516-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-J-2004" NAME="Deeks J 2004" NOTES="&lt;p&gt;Deeks J, Higgins J, Altman D.G. Analysing and presenting results. The Cochrane Reviewers Handbook 4..2.1. 2004: 68.&lt;br&gt;Deeks JJ, Higgins, JPT, Altman DG, editors. Analysing and presenting results. In: Alderson P, Green S, Higgins J, editors. Cochrane Reviewers&amp;#8217; Handbook 4.2.2 [updated December 2003]; Section 8. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp;amp; Sons, Ltd.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Deeks J, Higgins J, Altman DG, editors</AU>
<TI>Analysing and presenting results</TI>
<SO>In: Alderson P, Green S, Higgins J, editors. The Cochrane Reviewers Handbook 4.2.1 (updated December 2003)</SO>
<YR>Section 8. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp; Sons, Ltd</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dougados-1995" NAME="Dougados 1995" NOTES="&lt;p&gt;Dougados, M. Diagnostic features of ankylosing spondylitis. Br J Rheumatol 1995;34:301-305.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M</AU>
<TI>Diagnostic features of ankylosing spondylitis</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1995</YR>
<VL>34</VL>
<PG>301-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grade-Working-Group" NAME="Grade Working Group" TYPE="JOURNAL_ARTICLE">
<AU>Grade Working Group</AU>
<TI>Grading the quality of evidence and the strength of recommendations</TI>
<SO>BMJ 2004</SO>
<YR>In Press</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gran-1993" NAME="Gran 1993" NOTES="&lt;p&gt;Gran, J.T.; Husby,G.. The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 1993;22(5):319-334.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gran JT, Husby G</AU>
<TI>The epidemiology of ankylosing spondylitis</TI>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>5</NO>
<PG>319-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herbert-2005" NAME="Herbert 2005" TYPE="JOURNAL_ARTICLE">
<AU>Herbert RD, Bo K</AU>
<TI>Analysis of quality of interventions in systematic reviews</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>331</VL>
<NO>7515</NO>
<PG>507-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hidding-A-1993" NAME="Hidding A 1993" NOTES="&lt;p&gt;Hidding A, van der LS, de Witte L. Therapeutic effects of individual physical therapy in ankylosing spondylitis related to duration of disease. Clin Rheumatol 1993;12(3):334-340.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hidding A, van der LS, de Witte L</AU>
<TI>Therapeutic effects of individual physical therapy in ankylosing spondylitis related to duration of disease</TI>
<SO>Clinical Rheumatology</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>3</NO>
<PG>334-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" NAME="Higgins 2006" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Green S, editors.</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006].</TI>
<SO>The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley &amp; Sons, Ltd.</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khan-2002" NAME="Khan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Khan MA</AU>
<TI>Update on spondyloarthropathies</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2002</YR>
<VL>136</VL>
<NO>12</NO>
<PG>896-907</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2007" NAME="Lee 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lee W, Reveille J, Davis JC Jr, Learch TJ, Ward MM, Weisman MH</AU>
<TI>Are there gender differences in severity of AS? Results from the PSOAS cohort</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66</VL>
<PG>633-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mihai-2005" NAME="Mihai 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mihai B, van der Linden S, de Bie R, Stucki G</AU>
<TI>Experts' beliefs on physiotherapy for patients with ankylosing spondylitis and assessment of their knowledge on published evidence in the field. Results of a questionnaire among international ASAS members</TI>
<SO>Europa Medicophysica</SO>
<YR>2005</YR>
<VL>41</VL>
<NO>2</NO>
<PG>149-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Philadelphia-Panel" NAME="Philadelphia Panel" TYPE="JOURNAL_ARTICLE">
<AU>Philadelphia Panel</AU>
<TI>Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low-back pain</TI>
<SO>Physical Therapies</SO>
<YR>2001</YR>
<VL>81</VL>
<NO>10</NO>
<PG>1641-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robbins-2001" NAME="Robbins 2001" NOTES="&lt;p&gt;Robbins L, Burckhardt CS, Hannan MT. Clinical care. 2. ed. Atlanta, Georgia: ACR, 2001.&lt;/p&gt;" TYPE="BOOK">
<AU>Robbins L, Burckhardt CS, Hannan MT</AU>
<TI>Clinical Care</TI>
<YR>2001</YR>
<EN>2nd</EN>
<PB>ACR</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sieper-2002" NAME="Sieper 2002" TYPE="JOURNAL_ARTICLE">
<AU>Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A</AU>
<TI>Ankylosing spondylitis: an overview</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61, suppl 3</VL>
<PG>8-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sieper-2006" NAME="Sieper 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sieper J, Rudwaleit M, Khan MA, Braun J</AU>
<TI>Concepts and epidemiology of spondyloarthritis</TI>
<SO>Best Practice &amp; Research. Clinical Rheumatology</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>3</NO>
<PG>401-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2004" NAME="Tugwell 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tugwell P, Shea B, Boers M, Simons L, Strand V et al</AU>
<TI>Evidence-based Rheumatology</TI>
<SO>BMJ Books</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-der-Heijde-1999" NAME="Van der Heijde 1999" NOTES="&lt;p&gt;Van der Heijde, D.; Calin,A.; Dougados,M.; Khan,M.A.; van der,Linden S.; Bellamy,N.. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J.Rheumatol. 1999;26(4):951-954.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N</AU>
<TI>Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>4</NO>
<PG>951-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-der-Linden-1984" NAME="Van der Linden 1984" NOTES="&lt;p&gt;Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Van der Linden S, Valkenburg HA, Cats A</AU>
<TI>Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1984</YR>
<VL>27</VL>
<NO>4</NO>
<PG>361-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zochling-2006" NAME="Zochling 2006" TYPE="JOURNAL_ARTICLE">
<AU>Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B et al</AU>
<TI>ASAS/EULAR recommendations for the management of ankylosing spondylitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2006</YR>
<VL>65</VL>
<PG>442-52</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Altan-2006">
<CHAR_METHODS>
<P>Concealment of allocation: UNCLEAR<BR/>Co-intervention: MET <BR/>Exclusions or losses to follow up: MET<BR/>Outcome assessment: MET<BR/>Blinding of patients: <BR/>NOT MET</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>The study was carried out in Turkey, included 54 participants, age and gender not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: outpatient balneotherapy, 30 min once a day for 3 weeks + exercise program 30 min pr day<BR/>Group 2: 30 min exercise program pr day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Daily and night pain, morning stiffness, patients global, physician global, BASDAI, BASFI, DFI, tragus-wall, chest expansion, mod Schober, finger-tip-fibula distance, NHP<BR/>Points of assessment:<BR/>after treatment and 24 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Analay-2003">
<CHAR_METHODS>
<P>Concealment of allocation: MET<BR/>Co-intervention: UNCLEAR <BR/>Exclusions or losses to follow up: MET<BR/>Outcome assessment: MET<BR/>Blinding of patients: <BR/>NOT MET</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>The study was carried out in Turkey, included 45 participants, aged between 18 and 55 years, 84% men.<BR/>Inclusion criteria: <BR/>AMOR criteria, able to participate in exercise group<BR/>Exclusion criteria: <BR/>systemic organic involvement, hip and knee deformities, treated by physiotherapy last three months or practising regular exercises, receiving DMARDS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Intensive exercise program, 6 weeks, 3 days pr week, supervised. <BR/>Group 2: The control group was encouraged to practice an individualised home exercise program 3 days pr week for 6 weeks. They were called by phone every week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain at rest and during activity (VAS), duration of morning stiffness. <BR/>Anthopometric measures: chest expansion, tragus-to-wall-distance, Schober's test, finger-tip-to-floor-distance, intermalleolar distance<BR/>Physical condition: Aastrand test<BR/>Psychosocial measure: Beck Depression Scale<BR/>Points of assessment: baseline, after treatment and 3 months after treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The exercise program included stretching, mobilization and strengthening exercises, aerobic exercises and postural and respiratory exercises</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Codish-2005">
<CHAR_METHODS>
<P>Concealment of allocation: UNCLEAR<BR/>Co-intervention: UNCLEAR <BR/>Exclusions or losses to follow-up: MET<BR/>Outcome assessment: UNCLEAR<BR/>Blinding of patients: <BR/>NOT MET</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>The study was carried out at the Dead Sea area, included 28 participants, 93% men. Inclusion criteria: fulfilling NY criteria, back pain last months prior to enrollment<BR/>Exclusion criteria: concomitant psoriasis, other seroneg. SpA, malignacies, equilibrium disturbances, mental disorders, active noninflammatory spinal disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: balneotherapy + exposure to climatic conditions, 6 days pr week, 2 weeks<BR/>Group 2: fresh water pool + exposure to climatic conditions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Well-being, BASDAI, pain VAS, limitation of movement VAS.<BR/>Points of assessment: prior to arrival at Dead Sea, last day at Dead Sea, 1 and 3 months after end of treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005">
<CHAR_METHODS>
<P>Concealment of allocation: MET<BR/>Co-intervention: MET <BR/>Exclusions or losses to follow-up: UNCLEAR<BR/>Outcome assessment: MET<BR/>Blinding of patients: <BR/>NOT MET</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>The study was carried out in Spain, included 40 participants, 78% men, mean age 45.5 years. <BR/>Inclusion criteria: NY criteria<BR/>Exclusion criteria: functional class level IV, comorbidity, osteoporosis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: "experimental" muscle chain exercise program, 60 min/once a week/15 sessions/4 months<BR/>Group 2: "conventional" program, same procedure as group 1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BASMI, BASFI, BASDAI <BR/>Points of assessment: <BR/>baseline (pretreatment) and at end of 15 sessions (posttreatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Helliwell-1996">
<CHAR_METHODS>
<P>Concealment of allocation: NOT MET<BR/>Co-intervention: UNCLEAR <BR/>Exclusions or losses to follow-up: NOT MET<BR/>Outcome assessment: NOT MET<BR/>Blinding of patients: <BR/>NOT MET</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>The study was carried out in the UK, included 44 participants with a mean age 38.9 years, 89% men. <BR/>Inclusion criteria:<BR/>Fulfilling the New York criteria<BR/>Exclusion criteria: <BR/>participated in inpatient program within last year, peripheral joint involvement, unable to exercise.</P>
<P>Participants were divided into two disease severity groups (A and B, group B including patients with most severe disease) on the basis of anthropometric measures</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: inpatient, supervised group physiotherapy: 1 hour, 5 days pr week, 3 weeks + hydrotherapy 3 times pr week<BR/>Group 2: outpatient hydrotherapy and home-exercise: 2 times pr week , 6 weeks <BR/>Group 3: Home exercises: 6 weeks home exercise regime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1: Anthropometric measures: cervical rotation, chest expansion, Schober test<BR/>2. Subjective scores: Pain and stiffness (combined, VAS)<BR/>Points of assessment: two times prior to treatment, after treatment, 2, 4 and 6 months after treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Group 1: <BR/>+ occasionally massage and interference, included nine patients in severity group A and six patients in group B.<BR/>Group 2:<BR/>hydrotherapy + home exercise program, included 12 patients in severity group A and 3 in group B<BR/>Group 3:<BR/>included 9 patients in severity group A and 5 in group B</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hidding-1993">
<CHAR_METHODS>
<P>Concealment of allocation: MET<BR/>Co-intervention: MET<BR/>Exclusions or losses to follow-up: MET<BR/>Outcome assessment: MET<BR/>Blinding of patients: <BR/>NOT MET</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>The study was carried out in the Netherlands, included 144 participants, aged between 17 and 69 years, 76% men. <BR/>Inclusion criteria:<BR/>Fulfilling the New York criteria + one or more of the following features: Pain, stiffness or functional limitation last 3 months.<BR/>Exclusion criteria: <BR/>Hip replacement, BP &gt; 100mmHg at rest, pregnancy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Home-exercise program, the participants were encouraged to exercise for 30 minutes daily for 9 months.<BR/>Group 2: The home exercise program + supervised group once a week, 9 months.</P>
<P>
<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1: Spinal mobility: Thoraco-lumbar flexion (Miller method), cervical rotation<BR/>2: Physical fitness: Max work capacity, bicycle ergometer<BR/>3: Functioning or health status: Sickness Impact Profile, Health Assessment Questionnaire for Spondylarthropathies, Functional Index<BR/>4: Patient global assessment of wellbeing (VAS)<BR/>Points of assessments: baseline and subsequently every 3 months up to 9 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The exercise program focus on hip joints, peripheral joints and the entire spinal column.</P>
<P>The group exercise program consisted of: 1hour physical training, 1 hour sporting activity, 1 hour hydrotherapy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ince-2006">
<CHAR_METHODS>
<P>Concealment of allocation: UNCLEAR<BR/>Co-intervention: UNCLEAR<BR/>Exclusions or losses to follow-up: UNCLEAR<BR/>Outcome assessment: MET<BR/>Blinding of patients: <BR/>NOT MET</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>The study was carried out in Turkey, included 30 participants, mean age 35 years, 60% men.<BR/>Inclusion criteria: not decribed. Participants fulfilles NY criteria<BR/>Exclusion criteria: not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: multimodal supervised exercise program, 50 min/3days pr week/3 months.<BR/>Group 2: no intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Chest expansion, chin-to-chest distance, mod. Schober, occ-to-wall distance. Inclinometer: gross hip flexion, gross lumbar and thoracic flexion. Vital capacity, work capacity.<BR/>Points of assessments: baseline and after treatment (3 months)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kraag-1990">
<CHAR_METHODS>
<P>Concealment of allocation: UNCLEAR<BR/>Co-intervention: MET<BR/>Exclusions or losses to follow-up: MET<BR/>Outcome assessment: MET<BR/>Blinding of patients: <BR/>NOT MET</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>The study was carried out in Canada, included 53 participants between 19-73 years, 79% men. The participants were divided into two age groups: <BR/>18-35 years (n = 27) and 36 or over (n = 26). <BR/>Inclusion criteria:<BR/>Fulfilling the New York criteria + stable clinical status and drug therapy, absence of corticosteroid therapy for at least 3 months and immunosuppressive therapy for at least 6 months<BR/>Exclusion criteria: <BR/>patients with more than 10% loss of hip flexion+ contravening treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Home program, disease information and exercises. Planned visits 8-16 during the intervention period of 4 months<BR/>Group 2: no intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Main outcome: FFD<BR/>Secondary outcomes: the Toronto Activities of Daily Living Questionnaire, occiput-wall-distance, Schober test, pain (VAS), morning stiffness and sleep pattern.<BR/>Points of assessment: baseline and after intervention (4 months).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The treatment objectives were: disease education, pain control, improved posture and function.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lim-2005">
<CHAR_METHODS>
<P>Concealment of allocation: UNCLEAR<BR/>Co-intervention: UNCLEAR <BR/>Exclusions or losses to follow-up: MET<BR/>Outcome assessment: MET<BR/>Blinding of patients: <BR/>NOT MET</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>The study was carried out in Republic of Korea, included 50 participants, mean age 28 years, 78% men. <BR/>Inclusion criteria: outpatient without complications, lack of regular exercise previous 6 months, able to understand questionnaires, no changes in currrent medication, classified in the functional class II for AS<BR/>Exclusion criteria: <BR/>not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: exercise program, 30 min pr day/8 weeks<BR/>Group 2: no intervention, wait-list controls</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Joint mobility: FFD, cervical flexion, extension, shoulder flexion, hip abduction, knee flexion. BASFI, pain VAS, Beck Depression Inventory <BR/>Points of assessments: <BR/>baseline and after 8 weeks intervention</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sweeney-2002">
<CHAR_METHODS>
<P>Concealment of allocation: UNCLEAR<BR/>Co-intervention: UNCLEAR <BR/>Exclusions or losses to follow-up: NOT MET<BR/>Outcome assessment: UNCLEAR<BR/>Blinding of patients: <BR/>NOT MET</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>The study was carried out in the UK, included 155 participants aged between 16-65 years, 67% men. <BR/>Inclusion criteria:<BR/>members of the National AS Society or outpatients of the Royal National Hospital for Rheumatic Diseases<BR/>Exclusion criteria: not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: home-based intervention, exercise and educational program delivered by mail, 30 min, 6 months <BR/>Group 2: no intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Physical function (BASFI), disease activity (BASDAI), global well-being (BAS-G), exercise self efficacy (ESE), arthritis self efficacy (SES), quantity of AS exercise<BR/>Points of assessment: baseline and after intervention (6 months)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The mailed package included: video, educational booklet, exercise progress wall chart and exercise reminder stickers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Van-Tubergen-2001">
<CHAR_METHODS>
<P>Concealment of allocation: MET<BR/>Co-intervention: MET<BR/>Exclusions or losses to follow up: MET<BR/>Outcome assessment: MET<BR/>Blinding of patients: <BR/>NOT MET</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>The study was carried out in The Netherlands, Germany and Austria, included 120 participants (3 groups of 40). Group 1 included 67% men, mean (SD) age in the group was 48 (10), group 2 included 70% men, mean (SD) age 49 (9) and group 3 (control group) included 85% men, and the mean (SD) age in the group was 48 (10). <BR/>Inclusion criteria:<BR/>fulfilling the New York criteria, pain and stiffness or functional limitations for at least 3 months before entry and being able to stay away from home and work for 3 weeks<BR/>Exclusion criteria:<BR/> inability or unwillingness to participate in weekly group physical therapy, pregnancy, claustrophobia, severe comorbidity and/or AS for more than 20 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1: Spa- exercise therapy Austria<BR/>Group 2: Spa-exercise therapy Netherlands, 3 weeks<BR/>Group 3: staying home receiving weekly physiotherapy and drug treament as usual. <BR/>Weekly group physiotherapy consisted of 1 hour exercises, 1 hour sports and 1 hour hydrotherapy.<BR/>After the intervention period, all patients from the 3 groups engaged in weekly group physiotherapy sessions for another 37 weeks follow-up period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Main outcomes: Physical function (BASFI), pain, duration of morning stiffness, aggregated in a pooled index (PIC)<BR/>Secondary outcomes: disease activity (BASDAI), general health and functioning (HAQ-S), night pain, quality of life (ASQoL), intake of NSAIDs.<BR/>Points of assessment: baseline (2 weeks before spa therapy) and 1, 4, 7 and 10 months after start of spa-exercise therapy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The standardised spa-exercise therapy consisted of group physical exercises, walking, correction therapy (lying supine), hydrotherapy, sports and sauna</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Abbrevations:<BR/>BASDAI: Bath Ankylosing Disease Activity Index<BR/>BASFI: Bath Ankylosing Functional Index<BR/>BASMI: Bath Ankylosing Meterology Index<BR/>BAS-G: Bath Ankylosing Patient Global Score<BR/>VAS: visual analogue scale<BR/>FFD: fingertip to floor distance</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ammer-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>A systematic review of physiotherapy spondylarthropathies. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Backlund_x002c_-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>A five-year follow-up study on spinal mobility in AS patients, independent of interventions. The criteria of intervention and study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bakker-et-al-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>A study of cost effectiveness of supervised group physiotherapy. Based on data from an included RCT (Hidding 1993)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Band-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>A pre-post study of an inpatient management program, the criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bender-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>A review of the use of water for medical treatment, study design and participants not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bulstrode-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>A controlled pre-post study of the effect of daily passive stretching of the hip-joint. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-c2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>A middle term follow-up study. Control group data not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Falkenbach-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>A cross-sectional, retrospective study of exercise habits. The criteria of intervention and study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fisher-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>The objective was to establish the relation between restriction of chest expansion, lung function and work capacity. The criteria of intervention and study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gall-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>A review of effects of exercise in AS. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hafstrom-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>A pre-post study of physiotherapy in subtropic climate. The criteria of participants and study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heikkila-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Based on data from Viitanen 1995. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hidding-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>A follow-up study of an included RCT (Hidding 1993)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hidding-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>A study of the effect of group physiotherapy. Pre-post design, the criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hider-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>A study of the effect of exercising on body image. The criteria of outcome measures and study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Horslev_x002d_Petersen1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>A long-term study of the effect of exercises. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kraag-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>A follow-up study of an included RCT (Kraag 1990).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Driscoll-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>A study of effect of an inpatient program on neck mobility. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rasmussen-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>A description of a training program and preliminary results. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Russell-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>A pre-post study of physical training. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Santos-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>A screening study to evaluate how much exercise AS patients perform on a regular basis. The criteria of intervention and study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Seckin-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>A cross-sectional study of the relationship between pulmonary function and exercise tolerance. The criteria of study design and intervention not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stenstrom-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>A randomised controlled trial, comparing two methods of muscle training in patients with rheumatic diseases. The criteria of participants not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sundstrom-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>A cross-sectional study of exercise habits, the criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tegelberg-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>A study of effect of physical traing on the stomatognathic system in patients with RA and AS. The criteria of outcome measures not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tegelberg-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>A follow up of Tegelberg 1988.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tishler-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>A pre-post pilot study of the effects of spa therapy. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tomlinson-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pre-post study of an inpatient physiotherapy course. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Uhrin-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>A prospective, longitudinal study of exercising. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Tubergen-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>An evaluation of cost effectiveness of a spa-exercise course, based on data from an included RCT (van Tubergen 2001).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Tubergen-2002-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>A review on evidence for benefits of physical therapy and spa therapy. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Viitanen-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>A retrospective analysis of the efficacy of inpatient physiotherapy, the criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Viitanen-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>A follow-up study of an inpatient physiotherapy program. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Viitanen-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>A follow-up study of functional changes before and after an inpatient course. The criteria of study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wordsworth-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>A study of the effect of corticotrophin. Criteria of intervention and study design not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yurtukan-M">
<CHAR_REASON_FOR_EXCLUSION>
<P>A comparison of balneotherapy and NSAIDs. The balneotherapy group "had baths for 20 min a day", no exercising added, criteria for intervention not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Ahmad-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Pickering-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Altan-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Analay-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Codish-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Helliwell-1996">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hidding-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ince-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kraag-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lim-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sweeney-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Van-Tubergen-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Home exercise vs no intervention: pain</TITLE>
<TABLE COLS="10" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of patients</P>
</TH>
<TH>
<P>Baseline mean</P>
</TH>
<TH>
<P>Follow-up mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Sweeney 2002</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Home exercise prog.<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Pain (not reported)</P>
</TD>
<TD>
<P>75<BR/>
<BR/>80</P>
</TD>
<TD>
<P>6.49<BR/>
<BR/>6.06</P>
</TD>
<TD>
<P>6.80<BR/>
<BR/>6.24</P>
</TD>
<TD>
<P>0.13</P>
</TD>
<TD>
<P>2.1% (?)</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Kraag 1990</P>
</TD>
<TD>
<P>4 months</P>
</TD>
<TD>
<P>Home exercise prog<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Pain (0-100)</P>
</TD>
<TD>
<P>26<BR/>
<BR/>27</P>
</TD>
<TD>
<P>32.2<BR/>
<BR/>38.7</P>
</TD>
<TD>
<P>37.4<BR/>
<BR/>33.5</P>
</TD>
<TD>
<P>-10.4</P>
</TD>
<TD>
<P>26.9% (w) ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Home exercise vs no intervention: spinal mobility</TITLE>
<TABLE COLS="10" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (Scale)</P>
</TH>
<TH>
<P>No. of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Kraag 1994</P>
</TD>
<TD>
<P>4 months</P>
</TD>
<TD>
<P>Home exercise/educational program<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>FFD (cm)<BR/>
</P>
</TD>
<TD>
<P>26<BR/>
<BR/>27</P>
</TD>
<TD>
<P>23.6<BR/>
<BR/>27.5</P>
</TD>
<TD>
<P>15.3<BR/>
<BR/>29.5</P>
</TD>
<TD>
<P>10.3</P>
</TD>
<TD>
<P>37% (I) s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Kraag 1994</P>
</TD>
<TD>
<P>4 months</P>
</TD>
<TD>
<P>Home exercise/educational program<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Schober (cm)</P>
</TD>
<TD>
<P>26<BR/>
<BR/>27</P>
</TD>
<TD>
<P>13.7<BR/>
<BR/>13.3</P>
</TD>
<TD>
<P>11.3<BR/>
<BR/>10.6</P>
</TD>
<TD>
<P>0.3</P>
</TD>
<TD>
<P>2.3% (I) ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>s=significant<BR/>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Home vs no intervention: patient global assessment (BAS-G)</TITLE>
<TABLE COLS="10" ROWS="3">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of patients</P>
</TH>
<TH>
<P>Baseline mean</P>
</TH>
<TH>
<P>Follow-up mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Sweeney 2002</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Home exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>BAS-G (0-10)</P>
</TD>
<TD>
<P>75<BR/>
<BR/>80</P>
</TD>
<TD>
<P>4.0<BR/>
<BR/>3.7</P>
</TD>
<TD>
<P>3.60<BR/>
<BR/>3.61</P>
</TD>
<TD>
<P>0.31</P>
</TD>
<TD>
<P>8.4% (I) ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" NO="4">
<TITLE>Home exercise vs no intervention: BASFI</TITLE>
<TABLE COLS="10" ROWS="3">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of patients</P>
</TH>
<TH>
<P>Baseline mean</P>
</TH>
<TH>
<P>Follow-up mean</P>
</TH>
<TH>
<P>Absolute benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Sweeney 2002</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Home exercise prog<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>BASFI (0-10)</P>
</TD>
<TD>
<P>75<BR/>
<BR/>80</P>
</TD>
<TD>
<P>3.5<BR/>
<BR/>3.6</P>
</TD>
<TD>
<P>3.06<BR/>
<BR/>3.43</P>
</TD>
<TD>
<P>0.27</P>
</TD>
<TD>
<P>7.5% (I) ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" NO="5">
<TITLE>Home exercise vs no intervention: BASDAI</TITLE>
<TABLE COLS="10" ROWS="3">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of patients</P>
</TH>
<TH>
<P>Baseline mean</P>
</TH>
<TH>
<P>Follow-up mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Sweeney 2002</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Home exercise prog<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>BASDAI (0-10)</P>
</TD>
<TD>
<P>75<BR/>
<BR/>80</P>
</TD>
<TD>
<P>3.9<BR/>
<BR/>3.8</P>
</TD>
<TD>
<P>3.65<BR/>
<BR/>3.49</P>
</TD>
<TD>
<P>0.06</P>
</TD>
<TD>
<P>1.6% (W) ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" NO="6">
<TITLE>Supervised vs no intervention: spinal mobility</TITLE>
<TABLE COLS="10" ROWS="7">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of patients</P>
</TH>
<TH>
<P>Baseline mean</P>
</TH>
<TH>
<P>Follow-up mean</P>
</TH>
<TH>
<P>Absolute benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Ince 2006</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised exercise vs no intervention<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Chest expansion (cm)</P>
</TD>
<TD>
<P>15<BR/>
<BR/>15</P>
</TD>
<TD>
<P>2.40<BR/>
<BR/>1.87</P>
</TD>
<TD>
<P>3.23<BR/>
<BR/>1.77</P>
</TD>
<TD>
<P>0.93</P>
</TD>
<TD>
<P>49.7% (I) s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Ince 2006</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised exercise vs no intervention<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>FFD (cm)</P>
</TD>
<TD>
<P>15<BR/>
<BR/>15</P>
</TD>
<TD>
<P>18.13<BR/>
<BR/>18.70</P>
</TD>
<TD>
<P>14.67<BR/>
<BR/>18.07</P>
</TD>
<TD>
<P>3.23</P>
</TD>
<TD>
<P>17% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Ince 2006</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised exercise vs no intervention<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Occiput to wall (cm)</P>
</TD>
<TD>
<P>15<BR/>
<BR/>15</P>
</TD>
<TD>
<P>4.48<BR/>
<BR/>5.83</P>
</TD>
<TD>
<P>4.23<BR/>
<BR/>6.79</P>
</TD>
<TD>
<P>1.21</P>
</TD>
<TD>
<P>20.8% (I) s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Ince 2006</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised exercise vs no intervention<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Schober test (cm)</P>
</TD>
<TD>
<P>15<BR/>
<BR/>15</P>
</TD>
<TD>
<P>13.63<BR/>
<BR/>12.91</P>
</TD>
<TD>
<P>13.83<BR/>
<BR/>12.48</P>
</TD>
<TD>
<P>0.63</P>
</TD>
<TD>
<P>4.9% (I) s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Ince 2006</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised exercise vs no intervention<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Chin to chest (cm)</P>
</TD>
<TD>
<P>15<BR/>
<BR/>15</P>
</TD>
<TD>
<P>2.97<BR/>
<BR/>3.68</P>
</TD>
<TD>
<P>2.50<BR/>
<BR/>4.38</P>
</TD>
<TD>
<P>1.17</P>
</TD>
<TD>
<P>31.8% (I) s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>s=significant<BR/>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" NO="7">
<TITLE>Group PT vs individualised PT: pain and stiffness</TITLE>
<TABLE COLS="10" ROWS="10">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (Scale)</P>
</TH>
<TH>
<P>No. of patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Helliwell 1996</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Pain and stiffnes VAS (0-200)</P>
</TD>
<TD>
<P>15<BR/>
<BR/>14</P>
</TD>
<TD>
<P>81<BR/>
<BR/>81</P>
</TD>
<TD>
<P>41<BR/>
<BR/>80</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>48% (I), s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Helliwell 1996</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Pain and stiffnes VAS (0-200)</P>
</TD>
<TD>
<P>13<BR/>
<BR/>8</P>
</TD>
<TD>
<P>81<BR/>
<BR/>81</P>
</TD>
<TD>
<P>65<BR/>
<BR/>100</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>43% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Hidding 1993</P>
</TD>
<TD>
<P>9 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Pain (0-10)</P>
</TD>
<TD>
<P>67<BR/>
<BR/>68</P>
</TD>
<TD>
<P>3.4<BR/>
<BR/>4.0</P>
</TD>
<TD>
<P>3.6<BR/>
<BR/>4.7</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>12.5% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Hidding 1993</P>
</TD>
<TD>
<P>9 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Stiffness (0-10)</P>
</TD>
<TD>
<P>67<BR/>
<BR/>68</P>
</TD>
<TD>
<P>3.2<BR/>
<BR/>3.7</P>
</TD>
<TD>
<P>3.1<BR/>
<BR/>3.5</P>
</TD>
<TD>
<P>0.1</P>
</TD>
<TD>
<P>2.7% (W), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Pain rest</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22<BR/>
<BR/>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>3.82<BR/>
<BR/>3.13</P>
</TD>
<TD>
<P>3.30<BR/>
<BR/>3.09</P>
</TD>
<TD>
<P>0.48</P>
</TD>
<TD>
<P>15.3% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Pain rest</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>3.82<BR/>
<BR/>3.13</P>
</TD>
<TD>
<P>3.43<BR/>
<BR/>3.18</P>
</TD>
<TD>
<P>0.44</P>
</TD>
<TD>
<P>14% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Pain activity</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>4.47<BR/>
<BR/>4.59</P>
</TD>
<TD>
<P>4.21<BR/>
<BR/>4.31</P>
</TD>
<TD>
<P>0.2</P>
</TD>
<TD>
<P>4% (W), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Pain activity</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>4.47<BR/>
<BR/>4.59</P>
</TD>
<TD>
<P>4.65<BR/>
<BR/>5.31</P>
</TD>
<TD>
<P>0.54</P>
</TD>
<TD>
<P>11.7% (W), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>s=significant<BR/>ns=non-significanth</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" NO="8">
<TITLE>Group PT vs individualised PT: stiffness</TITLE>
<TABLE COLS="10" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of patients</P>
</TH>
<TH>
<P>Baseline mean</P>
</TH>
<TH>
<P>Follow-up mean</P>
</TH>
<TH>
<P>Absolute benefit</P>
</TH>
<TH>
<P>Relative difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Supervised group PT <BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Morning stiffness (min)</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>38.65<BR/>
<BR/>36.59</P>
</TD>
<TD>
<P>20.87<BR/>
<BR/>37.00</P>
</TD>
<TD>
<P>18.19</P>
</TD>
<TD>
<P>49.7% (I),ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised group PT <BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Morning stiffness (min)</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>38.65<BR/>
<BR/>36.59</P>
</TD>
<TD>
<P>24.04<BR/>
<BR/>35.54</P>
</TD>
<TD>
<P>13.56</P>
</TD>
<TD>
<P>37% (I),ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" NO="9">
<TITLE>Group PT vs individualised PT: BASFI</TITLE>
<TABLE COLS="10" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Supervised group PT<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>BASFI (0-100)</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>26.34<BR/>
<BR/>27.59</P>
</TD>
<TD>
<P>20.00<BR/>
<BR/>27.31</P>
</TD>
<TD>
<P>6.06</P>
</TD>
<TD>
<P>21.9% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised group PT<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>BASFI (0-100)</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>26.34<BR/>
<BR/>27.59</P>
</TD>
<TD>
<P>22.00<BR/>
<BR/>26.13</P>
</TD>
<TD>
<P>3.88</P>
</TD>
<TD>
<P>14% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-10" NO="10">
<TITLE>Group PT vs individualised PT: spinal mobility</TITLE>
<TABLE COLS="10" ROWS="19">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (Scale)</P>
</TH>
<TH>
<P>No. of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Modified Schobers test (cm)</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22<BR/>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>4.38<BR/>
<BR/>3.28</P>
</TD>
<TD>
<P>5.26<BR/>
<BR/>3.96</P>
</TD>
<TD>
<P>0.20</P>
</TD>
<TD>
<P>6% (I),ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Modified Schobers test (cm)</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>4.38<BR/>
<BR/>3.28</P>
</TD>
<TD>
<P>5.13<BR/>
<BR/>3.13</P>
</TD>
<TD>
<P>0.60</P>
</TD>
<TD>
<P>18% (I),s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>FFD (cm)</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>20.77<BR/>
<BR/>19.09</P>
</TD>
<TD>
<P>15.50<BR/>
<BR/>18.13</P>
</TD>
<TD>
<P>4.31</P>
</TD>
<TD>
<P>22.6% (I),ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>FFD (cm)</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>20.77<BR/>
<BR/>19.09</P>
</TD>
<TD>
<P>17.13<BR/>
<BR/>18.98</P>
</TD>
<TD>
<P>3.53</P>
</TD>
<TD>
<P>18.5% (I),ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Chest expansion (cm)</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>3.97<BR/>
<BR/>4.13</P>
</TD>
<TD>
<P>4.73<BR/>
<BR/>4.22</P>
</TD>
<TD>
<P>0.67</P>
</TD>
<TD>
<P>16.2% (I),ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Chest expansion (cm)</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>3.97<BR/>
<BR/>4.13</P>
</TD>
<TD>
<P>4.28<BR/>
<BR/>4.00</P>
</TD>
<TD>
<P>0.44</P>
</TD>
<TD>
<P>10.7% (I),ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Tragus Wall <BR/>Distance (cm)</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>16.97<BR/>
<BR/>15.45</P>
</TD>
<TD>
<P>14.02<BR/>
<BR/>14.81</P>
</TD>
<TD>
<P>2.31</P>
</TD>
<TD>
<P>14.9%(I),ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Analay 2003</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Tragus Wall <BR/>Distance (cm)</P>
</TD>
<TD>
<P>23<BR/>
<BR/>22</P>
</TD>
<TD>
<P>16.97<BR/>
<BR/>15.45</P>
</TD>
<TD>
<P>14.71<BR/>
<BR/>14.95</P>
</TD>
<TD>
<P>1.76</P>
</TD>
<TD>
<P>11.4%(I),ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Helliwell 1996</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Cervical rotation (degrees)</P>
</TD>
<TD>
<P>15<BR/>
<BR/>14</P>
</TD>
<TD>
<P>95.3<BR/>
<BR/>88.5</P>
</TD>
<TD>
<P>112.0<BR/>
<BR/>90.6</P>
</TD>
<TD>
<P>14.6</P>
</TD>
<TD>
<P>16.5%(I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Helliwell 1996</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Cervical rotation<BR/>(degrees)</P>
</TD>
<TD>
<P>15<BR/>
<BR/>14</P>
</TD>
<TD>
<P>95.3<BR/>
<BR/>88.5</P>
</TD>
<TD>
<P>101.5<BR/>
<BR/>97.9</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P>3.6%(W), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Helliwell 1996</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Chest expansion (cm)</P>
</TD>
<TD>
<P>15<BR/>
<BR/>14</P>
</TD>
<TD>
<P>54.5<BR/>
<BR/>50.2</P>
</TD>
<TD>
<P>63.0<BR/>
<BR/>55.7</P>
</TD>
<TD>
<P>3.0</P>
</TD>
<TD>
<P>6%(I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Helliwell 1996</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Chest expansion (cm)</P>
</TD>
<TD>
<P>15<BR/>
<BR/>14</P>
</TD>
<TD>
<P>54.5<BR/>
<BR/>50.2</P>
</TD>
<TD>
<P>68.5<BR/>
<BR/>71.3</P>
</TD>
<TD>
<P>7.1</P>
</TD>
<TD>
<P>14%(W), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Helliwell 1996</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Modified Schober test (cm)</P>
</TD>
<TD>
<P>15<BR/>
<BR/>14</P>
</TD>
<TD>
<P>34.2<BR/>
<BR/>38.6</P>
</TD>
<TD>
<P>39.0<BR/>
<BR/>41.1<BR/>
</P>
</TD>
<TD>
<P>2.3</P>
</TD>
<TD>
<P>6%(I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Helliwell 1996</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Modified Schober test (cm)</P>
</TD>
<TD>
<P>15<BR/>
<BR/>14</P>
</TD>
<TD>
<P>34.2<BR/>
<BR/>38.6</P>
</TD>
<TD>
<P>38.9<BR/>
<BR/>40.6</P>
</TD>
<TD>
<P>2.7</P>
</TD>
<TD>
<P>7%(I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Hidding 1993</P>
</TD>
<TD>
<P>9 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Spinal flexion (cm)</P>
</TD>
<TD>
<P>67<BR/>
<BR/>68<BR/>
</P>
</TD>
<TD>
<P>5.3<BR/>
<BR/>5.3</P>
</TD>
<TD>
<P>6.2<BR/>
<BR/>5.8</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>7.5%(I), s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Hidding 1993</P>
</TD>
<TD>
<P>9 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Chest expansion</P>
</TD>
<TD>
<P>67<BR/>
<BR/>68</P>
</TD>
<TD>
<P>3.7<BR/>
<BR/>4.0</P>
</TD>
<TD>
<P>4.3<BR/>
<BR/>4.4</P>
</TD>
<TD>
<P>0.2</P>
</TD>
<TD>
<P>5%(I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Hidding 1993</P>
</TD>
<TD>
<P>9 months</P>
</TD>
<TD>
<P>Supervised group physiotherapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Cerv. rotation</P>
</TD>
<TD>
<P>67<BR/>
<BR/>68</P>
</TD>
<TD>
<P>95<BR/>
<BR/>96</P>
</TD>
<TD>
<P>111<BR/>
<BR/>108</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>4.2%(I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>s=significant<BR/>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-11" NO="11">
<TITLE>Spa-therapy vs PT: pain</TITLE>
<TABLE COLS="10" ROWS="6">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (Scale)</P>
</TH>
<TH>
<P>No. of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End-of-Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy <BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Pain, VAS (0-10)<BR/>
</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40<BR/>
</P>
</TD>
<TD>
<P>4.6<BR/>
<BR/>4.8<BR/>
</P>
</TD>
<TD>
<P>3.6<BR/>
<BR/>4.7<BR/>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>0.9</P>
</TD>
<TD>
<P>18% (I), s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>16 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy <BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Pain, VAS (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>4.6<BR/>
<BR/>4.8<BR/>
</P>
</TD>
<TD>
<P>3.3<BR/>
<BR/>4.4</P>
</TD>
<TD>
<P>0.9</P>
</TD>
<TD>
<P>18.5% (I), s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>28 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Pain, VAS (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>4.6<BR/>
<BR/>4.8<BR/>
</P>
</TD>
<TD>
<P>4.2<BR/>
<BR/>4.8</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>8.3% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>40 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>Pain, VAS (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>4.6<BR/>
<BR/>4.8</P>
</TD>
<TD>
<P>4.7<BR/>
<BR/>5.0</P>
</TD>
<TD>
<P>-0.3</P>
</TD>
<TD>
<P>6.3% (W), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>s=significant<BR/>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-12" NO="12">
<TITLE>Spa-therapy vs PT: BASFI</TITLE>
<TABLE COLS="10" ROWS="6">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment Point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No. of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>BASFI (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>4.6<BR/>
<BR/>4.2</P>
</TD>
<TD>
<P>3.6<BR/>
<BR/>4.2</P>
</TD>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>24% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>16 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>BASFI (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>4.6<BR/>
<BR/>4.2</P>
</TD>
<TD>
<P>3.9<BR/>
<BR/>4.2</P>
</TD>
<TD>
<P>0.7</P>
</TD>
<TD>
<P>17% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>28 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>BASFI (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>4.6<BR/>
<BR/>4.2</P>
</TD>
<TD>
<P>4.2<BR/>
<BR/>4.3<BR/>
<BR/>
</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>11.9% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>40 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>BASFI (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>4.6<BR/>
<BR/>4.2</P>
</TD>
<TD>
<P>4.4<BR/>
<BR/>4.3</P>
</TD>
<TD>
<P>0.3</P>
</TD>
<TD>
<P>7.1% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-13" NO="13">
<TITLE>Spa-therapy vs PT: BAS-G</TITLE>
<TABLE COLS="10" ROWS="6">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (Scale)</P>
</TH>
<TH>
<P>No. of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control Group</P>
</TD>
<TD>
<P>BAS-G (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>5.3<BR/>
<BR/>4.9</P>
</TD>
<TD>
<P>3.7<BR/>
<BR/>4.6</P>
</TD>
<TD>
<P>1.3</P>
</TD>
<TD>
<P>27% (I), s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>16 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control Group</P>
</TD>
<TD>
<P>BAS-G (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>5.3<BR/>
<BR/>4.9</P>
</TD>
<TD>
<P>3.4<BR/>
<BR/>4.4</P>
</TD>
<TD>
<P>1.4</P>
</TD>
<TD>
<P>29%(I), s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>28 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control Group</P>
</TD>
<TD>
<P>BAS-G (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>5.3<BR/>
<BR/>4.9</P>
</TD>
<TD>
<P>3.5<BR/>
<BR/>4.5</P>
</TD>
<TD>
<P>1.4</P>
</TD>
<TD>
<P>29%(I), s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>40 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control Group</P>
</TD>
<TD>
<P>BAS-G (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>5.3<BR/>
<BR/>4.9</P>
</TD>
<TD>
<P>4.5<BR/>
<BR/>4.6</P>
</TD>
<TD>
<P>1.1</P>
</TD>
<TD>
<P>22.4%(I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>s=significant<BR/>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-14" NO="14">
<TITLE>Spa-therapy vs PT: BASDAI</TITLE>
<TABLE COLS="10" ROWS="6">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>BASDAI (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>4.9<BR/>
<BR/>4.5</P>
</TD>
<TD>
<P>3.8<BR/>
<BR/>4.1</P>
</TD>
<TD>
<P>0.7</P>
</TD>
<TD>
<P>15.6% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>16 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>BASDAI (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>4.9<BR/>
<BR/>4.5</P>
</TD>
<TD>
<P>3.3<BR/>
<BR/>3.9</P>
</TD>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>22.2% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>28 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>BASDAI (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>4.9<BR/>
<BR/>4.5</P>
</TD>
<TD>
<P>3.8<BR/>
<BR/>3.7</P>
</TD>
<TD>
<P>0.3</P>
</TD>
<TD>
<P>6.7% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Tubergen 2001</P>
</TD>
<TD>
<P>40 weeks</P>
</TD>
<TD>
<P>Spa exercise therapy<BR/>
<BR/>Control group</P>
</TD>
<TD>
<P>BASDAI (0-10)</P>
</TD>
<TD>
<P>80<BR/>
<BR/>40</P>
</TD>
<TD>
<P>4.9<BR/>
<BR/>4.5</P>
</TD>
<TD>
<P>4.1<BR/>
<BR/>4.0</P>
</TD>
<TD>
<P>0.3</P>
</TD>
<TD>
<P>6.7%(I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-evidence</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-15" NO="15">
<TITLE>Balneotherapy+exercise vs exercise: pain</TITLE>
<TABLE COLS="10" ROWS="6">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Outcone (scale)</P>
</TH>
<TH>
<P>No of patients</P>
</TH>
<TH>
<P>Baseline mean</P>
</TH>
<TH>
<P>Follow-up mean</P>
</TH>
<TH>
<P>Absolute benefit</P>
</TH>
<TH>
<P>Relative difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>3 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Pain day (0-10</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>3.46<BR/>
<BR/>3.53</P>
</TD>
<TD>
<P>1.96<BR/>
<BR/>2.00</P>
</TD>
<TD>
<P>0.03</P>
</TD>
<TD>
<P>0.8% (w), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Pain day (0-10</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>3.46<BR/>
<BR/>3.53</P>
</TD>
<TD>
<P>1.92<BR/>
<BR/>2.11</P>
</TD>
<TD>
<P>0.12</P>
</TD>
<TD>
<P>3.4% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>3 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Pain night (0-10)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>5.00<BR/>
<BR/>4.77</P>
</TD>
<TD>
<P>3.26<BR/>
<BR/>3.23</P>
</TD>
<TD>
<P>0.20</P>
</TD>
<TD>
<P>4.2% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Pain night (0-10)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>5.00<BR/>
<BR/>4.77</P>
</TD>
<TD>
<P>2.84<BR/>
<BR/>3.00</P>
</TD>
<TD>
<P>0.39</P>
</TD>
<TD>
<P>8.2% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-16" NO="16">
<TITLE>Balneotherapy+exercise vs exercise: stiffness</TITLE>
<TABLE COLS="10" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Asseesment point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>3 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Morning stiffness (0-3, 3 = more than 30 min)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>1.57<BR/>
<BR/>2.04</P>
</TD>
<TD>
<P>1.03<BR/>
<BR/>1.31</P>
</TD>
<TD>
<P>0.19</P>
</TD>
<TD>
<P>9.3% (W) s</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Morning stiffness (0-3, 3 = more than 30 min)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>1.57<BR/>
<BR/>2.04</P>
</TD>
<TD>
<P>1.12<BR/>
<BR/>1.27</P>
</TD>
<TD>
<P>0.32</P>
</TD>
<TD>
<P>15.7% (W) ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>s=significant<BR/>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-17" NO="17">
<TITLE>Balneotherapy+exercise vs exercise: patient global assessment</TITLE>
<TABLE COLS="10" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment Point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>3 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Patient global assessment (1-5)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>2.89<BR/>
<BR/>2.61</P>
</TD>
<TD>
<P>1.92<BR/>
<BR/>2.19</P>
</TD>
<TD>
<P>0.55</P>
</TD>
<TD>
<P>21.1% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Patient global assessment (1-5)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>2.89<BR/>
<BR/>2.61</P>
</TD>
<TD>
<P>2.12<BR/>
<BR/>2.23</P>
</TD>
<TD>
<P>0.39</P>
</TD>
<TD>
<P>14.9% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-18" NO="18">
<TITLE>Balneotherapy +exercise vs exercise: spinal mobility</TITLE>
<TABLE COLS="10" ROWS="10">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment Point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Mean</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>3 weeks<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Schober (cm)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>3.19<BR/>
<BR/>3.41</P>
</TD>
<TD>
<P>3.65<BR/>
<BR/>3.61</P>
</TD>
<TD>
<P>0.26</P>
</TD>
<TD>
<P>7.6% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Schober (cm)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>3.19<BR/>
<BR/>3.41</P>
</TD>
<TD>
<P>4.12<BR/>
<BR/>3.91</P>
</TD>
<TD>
<P>0.43</P>
</TD>
<TD>
<P>12.6% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>3 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>FFD (cm)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>5.03<BR/>
<BR/>3.94</P>
</TD>
<TD>
<P>3.76<BR/>
<BR/>2.73</P>
</TD>
<TD>
<P>0.06</P>
</TD>
<TD>
<P>1.5% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>FFD (cm)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>5.03<BR/>
<BR/>3.94</P>
</TD>
<TD>
<P>2.82<BR/>
<BR/>2.63</P>
</TD>
<TD>
<P>0.90</P>
</TD>
<TD>
<P>22.8% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>3 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Chest expansion (cm)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>4.11<BR/>
<BR/>4.57</P>
</TD>
<TD>
<P>4.94<BR/>
<BR/>5.02</P>
</TD>
<TD>
<P>0.38</P>
</TD>
<TD>
<P>8.3% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>Chest expansion (cm)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>4.11<BR/>
<BR/>4.57</P>
</TD>
<TD>
<P>4.97<BR/>
<BR/>4.94</P>
</TD>
<TD>
<P>0.49</P>
</TD>
<TD>
<P>10.7% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>3 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>OWD (cm)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>3.28<BR/>
<BR/>2.92</P>
</TD>
<TD>
<P>2.30<BR/>
<BR/>2.67</P>
</TD>
<TD>
<P>0.73</P>
</TD>
<TD>
<P>25% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>OWD (cm)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>3.28<BR/>
<BR/>2.92<BR/>
<BR/>
</P>
</TD>
<TD>
<P>1.76<BR/>
<BR/>2.48</P>
</TD>
<TD>
<P>1.08</P>
</TD>
<TD>
<P>37% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-19" NO="19">
<TITLE>Balneotherapy +exercise vs exercise: BASFI</TITLE>
<TABLE COLS="10" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment Point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>BASFI (0-10)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>1.28<BR/>
<BR/>0.91</P>
</TD>
<TD>
<P>0.50<BR/>
<BR/>0.61</P>
</TD>
<TD>
<P>0.48</P>
</TD>
<TD>
<P>52.7%</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>BASFI (0-10)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>1.28<BR/>
<BR/>0.91</P>
</TD>
<TD>
<P>0.38<BR/>
<BR/>0.54</P>
</TD>
<TD>
<P>0.53</P>
</TD>
<TD>
<P>58.2%</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-20" NO="20">
<TITLE>Balneotherapy +exercise vs exercise: BASDAI</TITLE>
<TABLE COLS="10" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment Point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>BASDAI (0-10)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>3.42<BR/>
<BR/>3.05</P>
</TD>
<TD>
<P>1.11<BR/>
<BR/>1.78</P>
</TD>
<TD>
<P>1.04</P>
</TD>
<TD>
<P>34%</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Altan 2006</P>
</TD>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>Balneotherapy + exercise<BR/>
<BR/>Control</P>
</TD>
<TD>
<P>BASDAI (0-10)</P>
</TD>
<TD>
<P>28<BR/>
<BR/>26</P>
</TD>
<TD>
<P>3.42<BR/>
<BR/>3.05</P>
</TD>
<TD>
<P>1.49<BR/>
<BR/>1.62</P>
</TD>
<TD>
<P>0.50</P>
</TD>
<TD>
<P>30.9%</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-21" NO="21">
<TITLE>Balneotherapy vs fresh water: pain</TITLE>
<TABLE COLS="10" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment Point</P>
</TH>
<TH>
<P>Tretament Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Codish 2005</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Balneotherapy<BR/>
<BR/>Fresh water therapy</P>
</TD>
<TD>
<P>Pain (0-10)</P>
</TD>
<TD>
<P>14<BR/>
<BR/>14</P>
</TD>
<TD>
<P>6.7<BR/>
<BR/>6.4</P>
</TD>
<TD>
<P>4.4<BR/>
<BR/>4.4</P>
</TD>
<TD>
<P>0.3</P>
</TD>
<TD>
<P>4.7%(I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Codish 2005</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Balneotherapy<BR/>
<BR/>Fresh water therapy</P>
</TD>
<TD>
<P>Pain (0-10)</P>
</TD>
<TD>
<P>14<BR/>
<BR/>14</P>
</TD>
<TD>
<P>6.7<BR/>
<BR/>6.4<BR/>
<BR/>
</P>
</TD>
<TD>
<P>5.2<BR/>
<BR/>5.1</P>
</TD>
<TD>
<P>0.2</P>
</TD>
<TD>
<P>3.1% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Codish 2005</P>
</TD>
<TD>
<P>12 weeks</P>
</TD>
<TD>
<P>Balneotherapy<BR/>
<BR/>Fresh water therapy</P>
</TD>
<TD>
<P>Pain (0-10)</P>
</TD>
<TD>
<P>14<BR/>
<BR/>14</P>
</TD>
<TD>
<P>6.7<BR/>
<BR/>6.4</P>
</TD>
<TD>
<P>5.1<BR/>
<BR/>4.9</P>
</TD>
<TD>
<P>0.1</P>
</TD>
<TD>
<P>1.6% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-22" NO="22">
<TITLE>Balneotherapy vs fresh water: movement</TITLE>
<TABLE COLS="10" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment Point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Codish 2005</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Balneotherapy<BR/>
<BR/>Fresh water therapy</P>
</TD>
<TD>
<P>movement (0-10)</P>
</TD>
<TD>
<P>14<BR/>
<BR/>14</P>
</TD>
<TD>
<P>6.3<BR/>
<BR/>7.1</P>
</TD>
<TD>
<P>5.9<BR/>
<BR/>5.1</P>
</TD>
<TD>
<P>-1.6</P>
</TD>
<TD>
<P>22.5% (W), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Codish 2005</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Balneotherapy<BR/>
<BR/>Fresh water therapy</P>
</TD>
<TD>
<P>movement (0-10)</P>
</TD>
<TD>
<P>14<BR/>
<BR/>14</P>
</TD>
<TD>
<P>6.3<BR/>
<BR/>7.1</P>
</TD>
<TD>
<P>5.9<BR/>
<BR/>5.4</P>
</TD>
<TD>
<P>-1.3</P>
</TD>
<TD>
<P>18.3% (W),ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Codish 2005</P>
</TD>
<TD>
<P>12 weeks</P>
</TD>
<TD>
<P>Balneotherapy<BR/>
<BR/>Fresh water therapy</P>
</TD>
<TD>
<P>movement (0-10)</P>
</TD>
<TD>
<P>14<BR/>
<BR/>14</P>
</TD>
<TD>
<P>6.3<BR/>
<BR/>7.1</P>
</TD>
<TD>
<P>6.1<BR/>
<BR/>5.6</P>
</TD>
<TD>
<P>-1.3</P>
</TD>
<TD>
<P>18.3% (W), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-evidence</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-23" NO="23">
<TITLE>Balneotherapy vs fresh water: BASDAI</TITLE>
<TABLE COLS="10" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment Point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Codish 2005</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Balneotherapy<BR/>
<BR/>Fresh water therapy</P>
</TD>
<TD>
<P>BASDAI (0-10)</P>
</TD>
<TD>
<P>14<BR/>
<BR/>14</P>
</TD>
<TD>
<P>4.86<BR/>
<BR/>6.10</P>
</TD>
<TD>
<P>3.96<BR/>
<BR/>4.16</P>
</TD>
<TD>
<P>-1.06</P>
</TD>
<TD>
<P>17.4% (w), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Codish 2005</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Balneotherapy<BR/>
<BR/>Fresh water therapy</P>
</TD>
<TD>
<P>BASDAI (0-10)</P>
</TD>
<TD>
<P>14<BR/>
<BR/>14</P>
</TD>
<TD>
<P>4.86<BR/>
<BR/>6.10</P>
</TD>
<TD>
<P>4.83<BR/>
<BR/>4.67</P>
</TD>
<TD>
<P>-1.4</P>
</TD>
<TD>
<P>23% (W), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>Codish 2005</P>
</TD>
<TD>
<P>12 weeks</P>
</TD>
<TD>
<P>Balneotherapy<BR/>
<BR/>Fresh water therapy</P>
</TD>
<TD>
<P>BASDAI (0-10)</P>
</TD>
<TD>
<P>14<BR/>
<BR/>14</P>
</TD>
<TD>
<P>4.86<BR/>
<BR/>6.10</P>
</TD>
<TD>
<P>4.77<BR/>
<BR/>4.86</P>
</TD>
<TD>
<P>-1.15</P>
</TD>
<TD>
<P>18.9% (W), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-24" NO="24">
<TITLE>Two diff exercise programs: spinal mobility</TITLE>
<TABLE COLS="10" ROWS="12">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment Point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>Conventional exercise</P>
</TD>
<TD>
<P>Tragus-wall (cm)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>7.0<BR/>
<BR/>6.2</P>
</TD>
<TD>
<P>5.1<BR/>
<BR/>4.3</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>one year</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>Conventional exercise<BR/>
</P>
</TD>
<TD>
<P>Tragus-wall (cm)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>7.0<BR/>
<BR/>6.2</P>
</TD>
<TD>
<P>5.2<BR/>
<BR/>5.4</P>
</TD>
<TD>
<P>1.2</P>
</TD>
<TD>
<P>19.3% (I), ns</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>Conventional exercise</P>
</TD>
<TD>
<P>Schober test (cm)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>1.8<BR/>
<BR/>2.5<BR/>
<BR/>
</P>
</TD>
<TD>
<P>2.4<BR/>
<BR/>2.7</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>16% (I), ns</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>one year</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>Conventional exercise</P>
</TD>
<TD>
<P>Schober test (cm)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>1.8<BR/>
<BR/>2.5</P>
</TD>
<TD>
<P>2.4<BR/>
<BR/>2.6</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>20% (I), ns</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>Conventional exercise</P>
</TD>
<TD>
<P>Cervical rotation (degrees)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>46<BR/>
<BR/>54</P>
</TD>
<TD>
<P>57<BR/>
<BR/>57</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>14.8% (I), ns</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>one year</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>Conventional exercise</P>
</TD>
<TD>
<P>Cervical rotation (degrees)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>46<BR/>
<BR/>54</P>
</TD>
<TD>
<P>52<BR/>
<BR/>55</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>9.3% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>Conventional exercise</P>
</TD>
<TD>
<P>Lumbar side flexion (cm)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>3.9<BR/>
<BR/>4.8</P>
</TD>
<TD>
<P>6.3<BR/>
<BR/>6.2</P>
</TD>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>20.8% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>one year</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>Conventional exercise</P>
</TD>
<TD>
<P>Lumbar side flexion (cm)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>3.9<BR/>
<BR/>4.8</P>
</TD>
<TD>
<P>5.4<BR/>
<BR/>5.4</P>
</TD>
<TD>
<P>0.9</P>
</TD>
<TD>
<P>18.8% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>Conventional exercise</P>
</TD>
<TD>
<P>Intermall. distance (cm)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>81.7<BR/>
<BR/>86.1</P>
</TD>
<TD>
<P>90.8<BR/>
<BR/>88.5</P>
</TD>
<TD>
<P>6.7</P>
</TD>
<TD>
<P>7.8% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>one year</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>Conventional exercise</P>
</TD>
<TD>
<P>Intermall. distance (cm)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>81.7<BR/>
<BR/>86.1</P>
</TD>
<TD>
<P>86.8<BR/>
<BR/>84.8</P>
</TD>
<TD>
<P>6.4</P>
</TD>
<TD>
<P>7.4% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-25" NO="25">
<TITLE>Two diff exercise programs: BASFI</TITLE>
<TABLE COLS="10" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>conventional exercise</P>
</TD>
<TD>
<P>BASFI (cm)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>51.8<BR/>
<BR/>47.0</P>
</TD>
<TD>
<P>45.7<BR/>
<BR/>46.5</P>
</TD>
<TD>
<P>5.6</P>
</TD>
<TD>
<P>11.9% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>one year</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>conventional exercise</P>
</TD>
<TD>
<P>BASFI (cm)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>51.8<BR/>
<BR/>47.0</P>
</TD>
<TD>
<P>46.7<BR/>
<BR/>48</P>
</TD>
<TD>
<P>6.1</P>
</TD>
<TD>
<P>13% (I), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-26" NO="26">
<TITLE>Two diff exercise programs: BASDAI</TITLE>
<TABLE COLS="10" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment Point</P>
</TH>
<TH>
<P>Treatment Group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>No of Patients</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>Follow-up Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
<TH>
<P>Level of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>after treatment</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>Conventional exercise</P>
</TD>
<TD>
<P>BASDAI (0-100)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>27.6<BR/>
<BR/>28.5</P>
</TD>
<TD>
<P>26.0<BR/>
<BR/>26.2</P>
</TD>
<TD>
<P>0.7</P>
</TD>
<TD>
<P>2.5% (W), ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P>D'Las Peñas 2005</P>
</TD>
<TD>
<P>one year</P>
</TD>
<TD>
<P>Experimental exercise<BR/>
<BR/>Conventional exercise</P>
</TD>
<TD>
<P>BASDAI (0-100)</P>
</TD>
<TD>
<P>20<BR/>
<BR/>20</P>
</TD>
<TD>
<P>27.6<BR/>
<BR/>28.5</P>
</TD>
<TD>
<P>26.8<BR/>
<BR/>28.0</P>
</TD>
<TD>
<P>0.3</P>
</TD>
<TD>
<P>1.1%, ns</P>
</TD>
<TD>
<P>Silver</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>ns=non-significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Individualised home exercise program versus no intervention</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="75" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>SES pain (scale not reported) 6 months</NAME>
<GROUP_LABEL_1>Home exerc.</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours home exerc.</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9248183969977967" CI_START="0.19518160300220255" EFFECT_SIZE="0.5599999999999996" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="6.24" ORDER="92895" SD_1="1.21" SD_2="1.1" SE="0.1861352554819568" STUDY_ID="STD-Sweeney-2002" TOTAL_1="75" TOTAL_2="80" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="75" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physical function (BASFI), VAS (cm), 6 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours home exerc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.48716409202780764" CI_START="-1.0871640920278072" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="3.4" ORDER="92896" SD_1="2.4" SD_2="2.6" SE="0.40162171256046403" STUDY_ID="STD-Sweeney-2002" TOTAL_1="75" TOTAL_2="80" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="75" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Patient global (BAS-G), VAS (cm)</NAME>
<GROUP_LABEL_1>Home exerc.</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours home exerc.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8501214341492169" CI_START="-0.8501214341492169" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="3.6" ORDER="92897" SD_1="2.6" SD_2="2.8" SE="0.4337433957230165" STUDY_ID="STD-Sweeney-2002" TOTAL_1="75" TOTAL_2="80" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="75" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Self-reported disease activity (BASDAI ), VAS (cm), 6 months</NAME>
<GROUP_LABEL_1>Home exercise</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours home exer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8612760863832505" CI_START="-0.46127608638325013" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="3.5" ORDER="92898" SD_1="2.0" SD_2="2.2" SE="0.3373919580152042" STUDY_ID="STD-Sweeney-2002" TOTAL_1="75" TOTAL_2="80" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Supervised exercises versus no intervention</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Chest expansion</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.6304010448278206" CI_START="0.2895989551721794" EFFECT_SIZE="1.46" ESTIMABLE="YES" MEAN_1="3.23" MEAN_2="1.77" ORDER="92899" SD_1="1.6" SD_2="1.67" SE="0.5971543630698292" STUDY_ID="STD-Ince-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Finger-tip-to-floor distance</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.825494380859057" CI_START="-14.605494380859055" EFFECT_SIZE="-3.389999999999999" ESTIMABLE="YES" MEAN_1="14.67" MEAN_2="18.06" ORDER="92900" SD_1="16.55" SD_2="14.74" SE="5.72229615917713" STUDY_ID="STD-Ince-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Occiput to wall distance</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.21973406001795803" CI_START="-4.900265939982042" EFFECT_SIZE="-2.5599999999999996" ESTIMABLE="YES" MEAN_1="4.23" MEAN_2="6.79" ORDER="92901" SD_1="3.27" SD_2="3.27" SE="1.1940351753612621" STUDY_ID="STD-Ince-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Modified Schober test</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.5642605669949177" CI_START="0.13573943300508162" EFFECT_SIZE="1.3499999999999996" ESTIMABLE="YES" MEAN_1="13.83" MEAN_2="12.48" ORDER="92902" SD_1="1.62" SD_2="1.77" SE="0.6195320814937674" STUDY_ID="STD-Ince-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Chin to chest distance</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6771291550306913" CI_START="-3.0828708449693085" EFFECT_SIZE="-1.88" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="4.38" ORDER="92903" SD_1="1.73" SD_2="1.63" SE="0.6137208920456704" STUDY_ID="STD-Ince-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Group physiotherapy (inpatient) versus individualised home exercises</NAME>
<CONT_OUTCOME CHI2="0.011569365337672922" CI_END="-0.5264733823182159" CI_START="-7.05175014799098" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.789111765154598" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.9143439486761524" P_Q="0.9143439486761524" P_Z="0.02283211473579372" Q="0.011569365337672922" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="22" UNITS="" WEIGHT="200.0" Z="2.2762322150589487">
<NAME>Pain/stiffness, VAS (cm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.144042121462052E-32" CI_END="-0.062343900411379494" CI_START="-7.737656099588622" DF="0.0" EFFECT_SIZE="-3.900000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-003.01.01" NO="1" P_CHI2="0.0" P_Z="0.046392545189335124" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="1.9918042006227705">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="-0.06234390041137905" CI_START="-7.737656099588621" EFFECT_SIZE="-3.9000000000000004" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="8.0" ORDER="1" SD_1="4.2" SD_2="6.1" SE="1.9580237850590942" STUDY_ID="STD-Helliwell-1996" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.972986988316817E-32" CI_END="2.6966390794656907" CI_START="-9.696639079465692" DF="0.0" EFFECT_SIZE="-3.5000000000000004" ESTIMABLE="YES" I2="100.0" ID="CMP-003.01.02" NO="2" P_CHI2="0.0" P_Z="0.26828037660029525" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="8" WEIGHT="100.0" Z="1.107031385549356">
<NAME>6 months</NAME>
<CONT_DATA CI_END="2.696639079465691" CI_START="-9.69663907946569" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="10.0" ORDER="1" SD_1="6.4" SD_2="7.4" SE="3.1616086460485953" STUDY_ID="STD-Helliwell-1996" TOTAL_1="13" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.4080640390628432" CI_START="-1.0080640390628437" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="1.0" P_Q="NaN" P_Z="0.7455745508510927" Q="-1.0872401772347545E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="46" TOTAL_2="44" UNITS="" WEIGHT="200.0" Z="0.32448014693997435">
<NAME>Pain at rest, VAS (cm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.973838774431781" CI_START="-1.5738387744317814" DF="0.0" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="1.0" P_Z="0.825103658225338" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="0.22098558367210036">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="1.973838774431781" CI_START="-1.5738387744317814" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="3.1" ORDER="92906" SD_1="2.3" SD_2="3.6" SE="0.9050364131298304" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0872401772347545E-33" CI_END="1.8498162737473138" CI_START="-1.4498162737473144" DF="0.0" EFFECT_SIZE="0.1999999999999997" ESTIMABLE="YES" I2="100.0" ID="CMP-003.02.02" NO="2" P_CHI2="0.0" P_Z="0.8121930196589239" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.00000000000001" Z="0.2375978484062692">
<NAME>3 months</NAME>
<CONT_DATA CI_END="1.8498162737473138" CI_START="-1.4498162737473144" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="3.2" ORDER="92907" SD_1="2.5" SD_2="3.1" SE="0.8417584643191682" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6089415728984897" CI_END="0.6466293549623081" CI_START="-1.8646208105252173" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6089957277814546" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.4351867857167473" P_Q="0.4351867857167473" P_Z="0.34180242902674673" Q="0.6089415728984897" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="46" TOTAL_2="44" UNITS="" WEIGHT="200.0" Z="0.9506099468657968">
<NAME>Pain activity, VAS (cm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6919147619945858" CI_START="-1.891914761994585" DF="0.0" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" NO="1" P_CHI2="1.0" P_Z="0.9129025295394714" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="0.10937819287555875">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="1.6919147619945858" CI_START="-1.891914761994585" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.3" ORDER="92908" SD_1="2.8" SD_2="3.3" SE="0.9142590252315759" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6599604732149695" CI_START="-2.8599604732149686" DF="0.0" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.02" NO="2" P_CHI2="1.0" P_Z="0.2205733589123935" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="1.2250050019905876">
<NAME>3 months</NAME>
<CONT_DATA CI_END="0.6599604732149695" CI_START="-2.8599604732149686" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="5.3" ORDER="92909" SD_1="2.8" SD_2="3.2" SE="0.8979555170897592" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.06327037643533315" CI_END="4.086530071670142" CI_START="-30.326784400098646" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.120127164214251" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.8013997096627697" P_Q="0.8013997096627697" P_Z="0.13505063649783255" Q="0.06327037643533315" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="46" TOTAL_2="44" UNITS="" WEIGHT="200.0" Z="1.4944783499735859">
<NAME>Morning stiffness (minutes)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.957905530801977" CI_START="-45.21790553080197" DF="0.0" EFFECT_SIZE="-16.13" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="1.0" P_Z="0.2771026833978403" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="1.086850995069202">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="12.957905530801977" CI_START="-45.21790553080197" EFFECT_SIZE="-16.13" ESTIMABLE="YES" MEAN_1="20.87" MEAN_2="37.0" ORDER="92910" SD_1="32.34" SD_2="62.01" SE="14.841040835568236" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.840909752090539" CI_START="-32.84090975209054" DF="0.0" EFFECT_SIZE="-11.5" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" NO="2" P_CHI2="1.0" P_Z="0.2908914864615949" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="1.0561679930258205">
<NAME>3 months</NAME>
<CONT_DATA CI_END="9.840909752090539" CI_START="-32.84090975209054" EFFECT_SIZE="-11.5" ESTIMABLE="YES" MEAN_1="24.04" MEAN_2="35.54" ORDER="92911" SD_1="36.24" SD_2="36.77" SE="10.888419338531172" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.27160024124249493" CI_END="47.132968484411194" CI_START="-17.714331636008325" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="14.709318424201436" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="0.6022603842266794" P_Q="0.6022603842266794" P_Z="0.37391840470810567" Q="0.27160024124249493" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="22" UNITS="" WEIGHT="200.0" Z="0.8891575838941734">
<NAME>Cervical rotation (degrees)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="62.44196986596627" CI_START="-19.64196986596626" DF="0.0" EFFECT_SIZE="21.400000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.01" NO="1" P_CHI2="1.0" P_Z="0.306800103523893" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="1.0219594577485978">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="62.44196986596627" CI_START="-19.64196986596626" EFFECT_SIZE="21.400000000000006" ESTIMABLE="YES" MEAN_1="112.0" MEAN_2="90.6" ORDER="1" SD_1="61.3" SD_2="51.3" SE="20.940165324312122" STUDY_ID="STD-Helliwell-1996" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.708714148936385E-34" CI_END="56.48551331222648" CI_START="-49.28551331222649" DF="0.0" EFFECT_SIZE="3.599999999999994" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-003.05.02" NO="2" P_CHI2="0.0" P_Z="0.8938629463924512" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="8" WEIGHT="100.00000000000001" Z="0.13341782848334294">
<NAME>6 months</NAME>
<CONT_DATA CI_END="56.48551331222648" CI_START="-49.28551331222649" EFFECT_SIZE="3.5999999999999943" ESTIMABLE="YES" MEAN_1="101.5" MEAN_2="97.9" ORDER="1" SD_1="61.4" SD_2="59.2" SE="26.98290056826588" STUDY_ID="STD-Helliwell-1996" TOTAL_1="13" TOTAL_2="8" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6204514140823914" CI_END="1.2432147387625216" CI_START="-0.3981688563676789" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.42252294119742134" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="0.7332814726116317" P_Q="0.4458091079578125" P_Z="0.3129444232308335" Q="0.5812852796472483" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="51" TOTAL_2="44" UNITS="" WEIGHT="200.0" Z="1.0090630244457766">
<NAME>Chest expansion (cm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.039166134435143" CI_END="1.5085589166756148" CI_START="-0.3360758750560021" DF="1.0" EFFECT_SIZE="0.5862415208098064" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" NO="1" P_CHI2="0.8431199843621939" P_Z="0.21284213166848676" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="36" WEIGHT="100.0" Z="1.2457883502789135">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="2.156000167991621" CI_START="-0.7560001679916211" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="5.6" ORDER="1" SD_1="2.1" SD_2="1.9" SE="0.7428708789938819" STUDY_ID="STD-Helliwell-1996" TOTAL_1="15" TOTAL_2="14" WEIGHT="40.1271162156873"/>
<CONT_DATA CI_END="1.7019699634361423" CI_START="-0.6819699634361409" EFFECT_SIZE="0.5100000000000007" ESTIMABLE="YES" MEAN_1="4.73" MEAN_2="4.22" ORDER="92914" SD_1="1.94" SD_2="2.13" SE="0.6081591155951072" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="59.8728837843127"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5984944262445038" CI_START="-1.9984944262445024" DF="0.0" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.02" NO="2" P_CHI2="1.0" P_Z="0.8274633311474807" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="8" WEIGHT="100.0" Z="0.2179560810352595">
<NAME>6 months</NAME>
<CONT_DATA CI_END="1.5984944262445038" CI_START="-1.9984944262445024" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="6.9" MEAN_2="7.1" ORDER="1" SD_1="2.5" SD_2="1.7" SE="0.9176160584739299" STUDY_ID="STD-Helliwell-1996" TOTAL_1="13" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.760731225560168" CI_END="1.4109451029286808" CI_START="-0.27856729910885236" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5661889019099142" ESTIMABLE="YES" I2="36.98447028697766" I2_Q="39.02715097367217" ID="CMP-003.07" NO="7" P_CHI2="0.19017981121713579" P_Q="0.19396581391897227" P_Z="0.18896565923431713" Q="3.2801485118997937" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="74" TOTAL_2="66" UNITS="" WEIGHT="300.0" Z="1.313645114237002">
<NAME>Schober test (cm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.480582713660374" CI_END="1.5851468162189473" CI_START="-0.7829136527267229" DF="1.0" EFFECT_SIZE="0.4011165817461122" ESTIMABLE="YES" I2="32.45902503293803" ID="CMP-003.07.01" NO="1" P_CHI2="0.22368370992095776" P_Z="0.5067022193734064" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="36" WEIGHT="100.0" Z="0.6639814009261548">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="1.329525554478487" CI_START="-1.7295255544784864" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="4.1" ORDER="1" SD_1="2.1" SD_2="2.1" SE="0.7803845206050668" STUDY_ID="STD-Helliwell-1996" TOTAL_1="15" TOTAL_2="14" WEIGHT="59.92556121692586"/>
<CONT_DATA CI_END="3.1703766316496402" CI_START="-0.5703766316496406" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="4.0" ORDER="92917" SD_1="3.2" SD_2="3.2" SE="0.954291326985053" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="40.07443878307414"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.84699692375402" CI_START="0.15300307624597997" DF="0.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.02" NO="2" P_CHI2="1.0" P_Z="0.03381044537595182" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="99.99999999999999" Z="2.1223251206682345">
<NAME>3 months</NAME>
<CONT_DATA CI_END="3.84699692375402" CI_START="0.15300307624597997" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="5.13" MEAN_2="3.13" ORDER="92919" SD_1="3.16" SD_2="3.16" SE="0.9423626853977399" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1685922649724183E-33" CI_END="1.391354094265168" CI_START="-1.7913540942651676" DF="0.0" EFFECT_SIZE="-0.19999999999999976" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-003.07.03" NO="3" P_CHI2="0.0" P_Z="0.8054294432296041" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="8" WEIGHT="100.0" Z="0.2463265707617506">
<NAME>6 months</NAME>
<CONT_DATA CI_END="1.391354094265168" CI_START="-1.7913540942651676" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="4.1" ORDER="1" SD_1="2.1" SD_2="1.6" SE="0.8119302736262328" STUDY_ID="STD-Helliwell-1996" TOTAL_1="13" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.01378593498449547" CI_END="4.267296549220314" CI_START="-8.752788344850948" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.242745897815317" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" NO="8" P_CHI2="0.9065323720601118" P_Q="0.9065323720601118" P_Z="0.4995369502707385" Q="0.01378593498449547" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="46" TOTAL_2="44" UNITS="" WEIGHT="200.0" Z="0.6752185138507917">
<NAME>Finger tip to floor distance (cm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.544349756188426" CI_START="-11.804349756188424" DF="0.0" EFFECT_SIZE="-2.629999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.01" NO="1" P_CHI2="1.0" P_Z="0.5742110305573157" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="0.5618605586584824">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="6.544349756188426" CI_START="-11.804349756188424" EFFECT_SIZE="-2.629999999999999" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="18.13" ORDER="92921" SD_1="12.97" SD_2="17.92" SE="4.680876704140752" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.218760454148155E-33" CI_END="7.389173190884829" CI_START="-11.089173190884832" DF="0.0" EFFECT_SIZE="-1.8500000000000016" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-003.08.02" NO="2" P_CHI2="0.0" P_Z="0.6947241618737421" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="0.39245214874599077">
<NAME>3 months</NAME>
<CONT_DATA CI_END="7.389173190884829" CI_START="-11.089173190884832" EFFECT_SIZE="-1.8500000000000014" ESTIMABLE="YES" MEAN_1="17.13" MEAN_2="18.98" ORDER="92922" SD_1="13.63" SD_2="17.64" SE="4.7139504928469345" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.08488221493974751" CI_END="1.320063629895194" CI_START="-2.375867914737647" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5279021424212266" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.09" NO="9" P_CHI2="0.7707870852129906" P_Q="0.7707870852129906" P_Z="0.5755501796453326" Q="0.08488221493974751" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="46" TOTAL_2="44" UNITS="" WEIGHT="200.0" Z="0.5598962935391294">
<NAME>Tragus to wall distance (cm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7641877604024114" CI_START="-3.3441877604024133" DF="0.0" EFFECT_SIZE="-0.7900000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.01" NO="1" P_CHI2="1.0" P_Z="0.544375996077173" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="0.6062089764077089">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="1.7641877604024114" CI_START="-3.3441877604024133" EFFECT_SIZE="-0.7900000000000009" ESTIMABLE="YES" MEAN_1="14.02" MEAN_2="14.81" ORDER="92923" SD_1="5.18" SD_2="3.42" SE="1.3031809668695544" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.4369701731163" CI_START="-2.916970173116297" DF="0.0" EFFECT_SIZE="-0.23999999999999844" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.02" NO="2" P_CHI2="1.0" P_Z="0.8605156368541954" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="0.17571781748394336">
<NAME>3 months</NAME>
<CONT_DATA CI_END="2.4369701731163" CI_START="-2.916970173116297" EFFECT_SIZE="-0.23999999999999844" ESTIMABLE="YES" MEAN_1="14.71" MEAN_2="14.95" ORDER="92924" SD_1="5.22" SD_2="3.87" SE="1.3658262061098558" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1761692459448249" CI_END="1.8138656758916438" CI_START="-12.980681225716683" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.583407774912519" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.10" NO="10" P_CHI2="0.6746862166038071" P_Q="0.6746862166038071" P_Z="0.13904240235152143" Q="0.1761692459448249" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="46" TOTAL_2="44" UNITS="" WEIGHT="200.0" Z="1.4793664480038666">
<NAME>BASFI</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.631868567122188" CI_START="-18.251868567122187" DF="0.0" EFFECT_SIZE="-7.309999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.01" NO="1" P_CHI2="1.0" P_Z="0.19039721986181934" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="1.3094049374745886">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="3.631868567122188" CI_START="-18.251868567122187" EFFECT_SIZE="-7.309999999999999" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="27.31" ORDER="92925" SD_1="16.76" SD_2="20.42" SE="5.58268858684662" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.908997425120436" CI_START="-14.168997425120434" DF="0.0" EFFECT_SIZE="-4.129999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.02" NO="2" P_CHI2="1.0" P_Z="0.42005797533203904" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="99.99999999999999" Z="0.8063206825708806">
<NAME>3 months</NAME>
<CONT_DATA CI_END="5.908997425120438" CI_START="-14.168997425120436" EFFECT_SIZE="-4.129999999999999" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="26.13" ORDER="92926" SD_1="17.15" SD_2="17.2" SE="5.122031580328398" STUDY_ID="STD-Analay-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Spa therapy in addition versus weekly group PT alone</NAME>
<CONT_OUTCOME CHI2="1.9319383391961624" CI_END="-0.2791228542890472" CI_START="-1.2457285654984258" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7624257098937365" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="0.5866528868687103" P_Q="0.5866528868687103" P_Z="0.001988759072273045" Q="1.9319383391961624" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="320" TOTAL_2="160" UNITS="" WEIGHT="400.0" Z="3.0919058618212896">
<NAME>Pain, VAS (cm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.123698109736891" CI_START="-2.01630189026311" DF="0.0" EFFECT_SIZE="-1.0700000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" NO="1" P_CHI2="1.0" P_Z="0.026680179721680134" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="2.2161653538225154">
<NAME>4 weeks</NAME>
<CONT_DATA CI_END="-0.123698109736891" CI_START="-2.01630189026311" EFFECT_SIZE="-1.0700000000000003" ESTIMABLE="YES" MEAN_1="3.62" MEAN_2="4.69" ORDER="92927" SD_1="2.67" SD_2="2.4" SE="0.48281595872547545" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.14363975703930365" CI_START="-2.036360242960697" DF="0.0" EFFECT_SIZE="-1.0900000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.02" NO="2" P_CHI2="1.0" P_Z="0.023979982786660532" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="2.257449802059558">
<NAME>16 weeks</NAME>
<CONT_DATA CI_END="-0.14363975703930376" CI_START="-2.036360242960697" EFFECT_SIZE="-1.0900000000000003" ESTIMABLE="YES" MEAN_1="3.32" MEAN_2="4.41" ORDER="92928" SD_1="2.52" SD_2="2.48" SE="0.4828457310570323" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4754213330255628" CI_START="-1.5754213330255624" DF="0.0" EFFECT_SIZE="-0.5499999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.03" NO="3" P_CHI2="1.0" P_Z="0.29314110643459146" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="1.0512558660315647">
<NAME>28 weeks</NAME>
<CONT_DATA CI_END="0.4754213330255628" CI_START="-1.5754213330255624" EFFECT_SIZE="-0.5499999999999998" ESTIMABLE="YES" MEAN_1="4.21" MEAN_2="4.76" ORDER="92929" SD_1="2.93" SD_2="2.58" SE="0.5231837631272591" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6548339265997596" CI_START="-1.2548339265997592" DF="0.0" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.04" NO="4" P_CHI2="1.0" P_Z="0.5380248278941026" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="0.615802579885167">
<NAME>40 weeks</NAME>
<CONT_DATA CI_END="0.6548339265997596" CI_START="-1.2548339265997592" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="4.67" MEAN_2="4.97" ORDER="92930" SD_1="2.75" SD_2="2.39" SE="0.4871691184794045" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.5267002372840266" CI_END="0.17771427158389455" CI_START="-0.6549411416711965" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.23861343504365098" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" NO="2" P_CHI2="0.6761218153136738" P_Q="0.6761218153136738" P_Z="0.26129704258834563" Q="1.5267002372840266" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="320" TOTAL_2="160" UNITS="" WEIGHT="400.0" Z="1.1233308076018422">
<NAME>BASFI</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.19238674844085335" CI_START="-1.4323867484408535" DF="0.0" EFFECT_SIZE="-0.6200000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" NO="1" P_CHI2="1.0" P_Z="0.13470271000274886" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="1.4958117826848156">
<NAME>4 weeks</NAME>
<CONT_DATA CI_END="0.19238674844085335" CI_START="-1.4323867484408535" EFFECT_SIZE="-0.6200000000000001" ESTIMABLE="YES" MEAN_1="3.62" MEAN_2="4.24" ORDER="92931" SD_1="2.08" SD_2="2.17" SE="0.414490651281787" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5577893833353296" CI_START="-1.1577893833353292" DF="0.0" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.02" NO="2" P_CHI2="1.0" P_Z="0.49304716425322614" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="0.6854703576252559">
<NAME>16 weeks</NAME>
<CONT_DATA CI_END="0.5577893833353296" CI_START="-1.1577893833353292" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="3.91" MEAN_2="4.21" ORDER="92932" SD_1="2.24" SD_2="2.27" SE="0.4376556865847855" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0103504062465827E-33" CI_END="0.7557212632631696" CI_START="-0.9557212632631689" DF="0.0" EFFECT_SIZE="-0.09999999999999963" ESTIMABLE="YES" I2="100.0" ID="CMP-004.02.03" NO="3" P_CHI2="0.0" P_Z="0.818836010193678" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.00000000000001" Z="0.22904233757917947">
<NAME>28 weeks</NAME>
<CONT_DATA CI_END="0.7557212632631697" CI_START="-0.955721263263169" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.24" MEAN_2="4.34" ORDER="92933" SD_1="2.36" SD_2="2.2" SE="0.43660050389343347" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8785920436818969" CI_START="-0.7385920436818963" DF="0.0" EFFECT_SIZE="0.07000000000000028" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.04" NO="4" P_CHI2="1.0" P_Z="0.8652661019431906" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="0.1696745348780335">
<NAME>40 weeks</NAME>
<CONT_DATA CI_END="0.8785920436818969" CI_START="-0.7385920436818963" EFFECT_SIZE="0.07000000000000028" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="4.33" ORDER="92934" SD_1="2.07" SD_2="2.16" SE="0.4125545418487112" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.5792367177931514" CI_END="-0.2779455992786324" CI_START="-1.2084893911754526" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7432174952270425" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" NO="3" P_CHI2="0.461141293150243" P_Q="0.461141293150243" P_Z="0.0017432283942213245" Q="2.5792367177931514" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="320" TOTAL_2="160" UNITS="" WEIGHT="400.0" Z="3.130813479193231">
<NAME>Patient global</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.08499919735363903" CI_START="-1.7750008026463613" DF="0.0" EFFECT_SIZE="-0.9300000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" NO="1" P_CHI2="1.0" P_Z="0.030996465531807963" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="99.99999999999999" Z="2.157118075999144">
<NAME>4 weeks</NAME>
<CONT_DATA CI_END="-0.08499919735363903" CI_START="-1.7750008026463613" EFFECT_SIZE="-0.9300000000000002" ESTIMABLE="YES" MEAN_1="3.68" MEAN_2="4.61" ORDER="92935" SD_1="2.51" SD_2="2.07" SE="0.43113078062230714" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.02144517023744963" CI_START="-1.8385548297625507" DF="0.0" EFFECT_SIZE="-0.9300000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.02" NO="2" P_CHI2="1.0" P_Z="0.04483211951294613" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="2.0062262022189987">
<NAME>16 weeks</NAME>
<CONT_DATA CI_END="-0.02144517023744963" CI_START="-1.8385548297625507" EFFECT_SIZE="-0.9300000000000002" ESTIMABLE="YES" MEAN_1="3.43" MEAN_2="4.36" ORDER="92936" SD_1="2.46" SD_2="2.36" SE="0.4635569004987413" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.01939091000925308" CI_START="-2.019390910009254" DF="0.0" EFFECT_SIZE="-1.0000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.03" NO="3" P_CHI2="1.0" P_Z="0.05452006892076487" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="1.922681441727064">
<NAME>28 weeks</NAME>
<CONT_DATA CI_END="0.01939091000925308" CI_START="-2.019390910009254" EFFECT_SIZE="-1.0000000000000004" ESTIMABLE="YES" MEAN_1="3.53" MEAN_2="4.53" ORDER="92937" SD_1="2.99" SD_2="2.52" SE="0.52010696015339" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9381599819527537" CI_START="-1.0181599819527538" DF="0.0" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.04" NO="4" P_CHI2="1.0" P_Z="0.9361187395179111" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="0.08014901532271944">
<NAME>40 weeks</NAME>
<CONT_DATA CI_END="0.9381599819527539" CI_START="-1.018159981952754" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" MEAN_1="4.53" MEAN_2="4.57" ORDER="92938" SD_1="2.65" SD_2="2.54" SE="0.49907038581747165" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.01368009154452" CI_END="0.23777203639412478" CI_START="-0.535782428556363" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.14900519608111915" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" NO="4" P_CHI2="0.5695722471125337" P_Q="0.5695722471125337" P_Z="0.450205541390871" Q="2.01368009154452" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="320" TOTAL_2="160" UNITS="" WEIGHT="400.0" Z="0.7550724119910935">
<NAME>BASDAI</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5330531140920471" CI_START="-1.0530531140920476" DF="0.0" EFFECT_SIZE="-0.26000000000000023" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.01" NO="1" P_CHI2="1.0" P_Z="0.5205043889068641" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="0.6425681041096925">
<NAME>4 weeks</NAME>
<CONT_DATA CI_END="0.5330531140920471" CI_START="-1.0530531140920476" EFFECT_SIZE="-0.26000000000000023" ESTIMABLE="YES" MEAN_1="3.82" MEAN_2="4.08" ORDER="92939" SD_1="2.24" SD_2="2.01" SE="0.4046263708657655" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.22251086493067196" CI_START="-1.4025108649306726" DF="0.0" EFFECT_SIZE="-0.5900000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.02" NO="2" P_CHI2="1.0" P_Z="0.154673446138706" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="1.4232163541312164">
<NAME>16 weeks</NAME>
<CONT_DATA CI_END="0.22251086493067196" CI_START="-1.4025108649306726" EFFECT_SIZE="-0.5900000000000003" ESTIMABLE="YES" MEAN_1="3.32" MEAN_2="3.91" ORDER="92940" SD_1="2.22" SD_2="2.1" SE="0.4145539771851188" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8749276929308389" CI_START="-0.5949276929308396" DF="0.0" EFFECT_SIZE="0.13999999999999968" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.03" NO="3" P_CHI2="1.0" P_Z="0.7088781427381085" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="0.37336320358447705">
<NAME>28 weeks</NAME>
<CONT_DATA CI_END="0.8749276929308389" CI_START="-0.5949276929308396" EFFECT_SIZE="0.13999999999999968" ESTIMABLE="YES" MEAN_1="3.82" MEAN_2="3.68" ORDER="92941" SD_1="2.2" SD_2="1.79" SE="0.374969998799904" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.790626392743304" CI_START="-0.7306263927433035" DF="0.0" EFFECT_SIZE="0.03000000000000025" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.04" NO="4" P_CHI2="1.0" P_Z="0.9383822769262752" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0" Z="0.07730328594585802">
<NAME>40 weeks</NAME>
<CONT_DATA CI_END="0.790626392743304" CI_START="-0.7306263927433035" EFFECT_SIZE="0.03000000000000025" ESTIMABLE="YES" MEAN_1="4.07" MEAN_2="4.04" ORDER="92942" SD_1="2.18" SD_2="1.91" SE="0.3880818212696905" STUDY_ID="STD-Van-Tubergen-2001" TOTAL_1="80" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Two different exercise programs</NAME>
<CONT_OUTCOME CHI2="0.38037276531000375" CI_END="1.7417847413195813" CI_START="-1.3597383358422137" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.19102320273868373" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" NO="1" P_CHI2="0.5374041271818869" P_Q="0.5374041271818869" P_Z="0.8092227437552757" Q="0.38037276531000375" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="0.24142886463506533">
<NAME>Tragus to wall</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.279954751992724" CI_START="-1.6799547519927245" DF="0.0" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.01" NO="1" P_CHI2="1.0" P_Z="0.5272183185053736" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.6322579822765424">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="3.279954751992724" CI_START="-1.6799547519927245" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="4.3" ORDER="92943" SD_1="3.9" SD_2="4.1" SE="1.2653062870309306" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months follow-up</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7872140467683801" CI_START="-2.1872140467683803" DF="0.0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.03" NO="3" P_CHI2="1.0" P_Z="0.8436260667413662" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.19725746078811807">
<NAME>one year follow up</NAME>
<CONT_DATA CI_END="1.7872140467683801" CI_START="-2.1872140467683803" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="5.4" ORDER="92944" SD_1="3.4" SD_2="3.0" SE="1.0139033484509261" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0357781753130591" CI_END="0.26960715872318797" CI_START="-0.7658504503153173" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.24812164579606463" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" NO="2" P_CHI2="0.8499743812019485" P_Q="0.8499743812019485" P_Z="0.34756998511898796" Q="0.0357781753130591" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="0.9393131796030997">
<NAME>Modified Schober</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.1251640765652256E-32" CI_END="0.4463320500961003" CI_START="-1.0463320500961009" DF="0.0" EFFECT_SIZE="-0.3000000000000003" ESTIMABLE="YES" I2="100.0" ID="CMP-005.02.01" NO="1" P_CHI2="0.0" P_Z="0.4307911281360377" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7878385971583362">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="0.44633205009610033" CI_START="-1.0463320500961009" EFFECT_SIZE="-0.30000000000000027" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.7" ORDER="92945" SD_1="1.1" SD_2="1.3" SE="0.38078865529319544" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5188019277821672" CI_START="-0.9188019277821675" DF="0.0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.02" NO="2" P_CHI2="1.0" P_Z="0.5855184056647382" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.5453418831492123">
<NAME>one year follow up</NAME>
<CONT_DATA CI_END="0.5188019277821672" CI_START="-0.9188019277821675" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.6" ORDER="92946" SD_1="1.0" SD_2="1.3" SE="0.366742416417845" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2567760342368045" CI_END="3.9979866731728126" CI_START="-7.464463135369675" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.733238231098431" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" NO="3" P_CHI2="0.6123438035607057" P_Q="0.6123438035607057" P_Z="0.5533600453272975" Q="0.2567760342368045" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="0.5927327170582907">
<NAME>Cervical rotation (degrees)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.819837930430245" CI_START="-8.819837930430245" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="8.819837930430245" CI_START="-8.819837930430245" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="57.0" MEAN_2="57.0" ORDER="92947" SD_1="18.0" SD_2="9.0" SE="4.5" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.540131997934325" CI_START="-10.540131997934324" DF="0.0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.02" NO="2" P_CHI2="1.0" P_Z="0.43550103807246043" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7798128673650545">
<NAME>one year follow up</NAME>
<CONT_DATA CI_END="4.540131997934325" CI_START="-10.540131997934324" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="52.0" MEAN_2="55.0" ORDER="92948" SD_1="14.0" SD_2="10.0" SE="3.847076812334269" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.008153281695882534" CI_END="1.1302640593745257" CI_START="-1.0363382542379584" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.04696290256828356" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" NO="4" P_CHI2="0.9280523771421362" P_Q="0.9280523771421362" P_Z="0.9322870768695574" Q="0.008153281695882534" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="0.08496769071553993">
<NAME>Lumbar side flexion</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6807811242741761" CI_START="-1.4807811242741769" DF="0.0" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" NO="1" P_CHI2="1.0" P_Z="0.9013255234773452" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.12398705642692784">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="1.6807811242741761" CI_START="-1.4807811242741769" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="6.2" ORDER="92949" SD_1="2.5" SD_2="2.6" SE="0.8065358020571685" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.487508077530948" CI_START="-1.487508077530948" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>one year follow up</NAME>
<CONT_DATA CI_END="1.487508077530948" CI_START="-1.487508077530948" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="5.4" ORDER="92950" SD_1="2.4" SD_2="2.4" SE="0.758946638440411" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.005224660397074091" CI_END="6.170878713379157" CI_START="-1.906441235148577" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.13221873911529" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.05" NO="5" P_CHI2="0.942377638549608" P_Q="0.942377638549608" P_Z="0.3007777674398501" Q="0.005224660397074091" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="1.034766967870104">
<NAME>Intermalleolar distance</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.383470578425374" CI_START="-3.783470578425381" DF="0.0" EFFECT_SIZE="2.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.01" NO="1" P_CHI2="1.0" P_Z="0.4586869212759641" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7410107612633398">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="8.383470578425374" CI_START="-3.783470578425381" EFFECT_SIZE="2.299999999999997" ESTIMABLE="YES" MEAN_1="90.8" MEAN_2="88.5" ORDER="92951" SD_1="11.2" SD_2="8.2" SE="3.103868553917836" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.400403259638098" CI_START="-3.4004032596380984" DF="0.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.02" NO="2" P_CHI2="1.0" P_Z="0.46792559796975586" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7258583814244267">
<NAME>one year follow up</NAME>
<CONT_DATA CI_END="7.400403259638099" CI_START="-3.4004032596380993" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="86.8" MEAN_2="84.8" ORDER="92952" SD_1="10.0" SD_2="7.2" SE="2.755358415887124" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.003053006295298981" CI_END="7.789469278863271" CI_START="-9.91785918440325" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0641949527699897" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.06" NO="6" P_CHI2="0.9559361233648752" P_Q="0.9559361233648752" P_Z="0.8137553023256734" Q="0.003053006295298981" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="0.23558424234185277">
<NAME>BASFI</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.848745410945343E-34" CI_END="12.092332614922464" CI_START="-13.692332614922458" DF="0.0" EFFECT_SIZE="-0.799999999999997" ESTIMABLE="YES" I2="100.0" ID="CMP-005.06.01" NO="1" P_CHI2="0.0" P_Z="0.9031996235255174" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.12162044173582376">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="12.092332614922464" CI_START="-13.692332614922458" EFFECT_SIZE="-0.7999999999999972" ESTIMABLE="YES" MEAN_1="45.7" MEAN_2="46.5" ORDER="92953" SD_1="20.6" SD_2="21.0" SE="6.577841591282052" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2766888039751219E-33" CI_END="10.879958024023571" CI_START="-13.479958024023565" DF="0.0" EFFECT_SIZE="-1.2999999999999974" ESTIMABLE="YES" I2="100.0" ID="CMP-005.06.02" NO="2" P_CHI2="0.0" P_Z="0.8342981395138652" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.20919227922432249">
<NAME>one year follow up</NAME>
<CONT_DATA CI_END="10.879958024023571" CI_START="-13.479958024023565" EFFECT_SIZE="-1.2999999999999972" ESTIMABLE="YES" MEAN_1="46.7" MEAN_2="48.0" ORDER="92954" SD_1="19.9" SD_2="19.4" SE="6.2143784886342415" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.05058808650562793" CI_END="3.6461289116841544" CI_START="-5.06623767607014" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7100543821929929" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.07" NO="7" P_CHI2="0.8220431022445326" P_Q="0.8220431022445326" P_Z="0.7493681986841119" Q="0.05058808650562793" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="0.31947255711649886">
<NAME>BASDAI</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.023464353529193" CI_START="-6.423464353529192" DF="0.0" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-005.07.01" NO="1" P_CHI2="1.0" P_Z="0.9497774387397562" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.06298626852192361">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="6.023464353529193" CI_START="-6.423464353529192" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="26.2" ORDER="92955" SD_1="11.3" SD_2="8.6" SE="3.1752952618614856" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.899551514531427" CI_START="-7.299551514531426" DF="0.0" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-005.07.02" NO="2" P_CHI2="1.0" P_Z="0.6997966115579373" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.3855950352816626">
<NAME>one year follow up</NAME>
<CONT_DATA CI_END="4.899551514531427" CI_START="-7.299551514531426" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" MEAN_1="26.8" MEAN_2="28.0" ORDER="92956" SD_1="10.7" SD_2="8.9" SE="3.112073263919087" STUDY_ID="STD-D_x0027_Las-Pe_x00f1_as-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Balneotherapy and exercises versus exercises alone</NAME>
<CONT_OUTCOME CHI2="0.0737632496899511" CI_END="0.4286745867299092" CI_START="-0.6530400741752961" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1121827437226934" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" NO="1" P_CHI2="0.7859342924041697" P_Q="0.7859342924041697" P_Z="0.6843540254113847" Q="0.0737632496899511" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="52" UNITS="" WEIGHT="200.0" Z="0.4065289032865097">
<NAME>Pain day</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.280166515489181E-34" CI_END="0.7109143308264763" CI_START="-0.7909143308264763" DF="0.0" EFFECT_SIZE="-0.04000000000000004" ESTIMABLE="YES" I2="100.0" ID="CMP-006.01.01" NO="1" P_CHI2="0.0" P_Z="0.9168486432615591" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.10440413261964879">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="0.7109143308264763" CI_START="-0.7909143308264763" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.96" MEAN_2="2.0" ORDER="92957" SD_1="1.37" SD_2="1.44" SE="0.3831265965852397" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.589671495417518" CI_START="-0.9696714954175178" DF="0.0" EFFECT_SIZE="-0.18999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.02" NO="2" P_CHI2="1.0" P_Z="0.6329147990209116" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.4776282822333935">
<NAME>24 week follow up</NAME>
<CONT_DATA CI_END="0.589671495417518" CI_START="-0.9696714954175178" EFFECT_SIZE="-0.18999999999999995" ESTIMABLE="YES" MEAN_1="1.92" MEAN_2="2.11" ORDER="92958" SD_1="1.32" SD_2="1.58" SE="0.39779888894258625" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.08216565567635467" CI_END="0.5914597506727128" CI_START="-0.6954781292072452" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.05200918926726616" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.02" NO="2" P_CHI2="0.774383764989009" P_Q="0.774383764989009" P_Z="0.8741285632830367" Q="0.08216565567635467" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="52" UNITS="" WEIGHT="200.0" Z="0.15841656294782017">
<NAME>Pain night</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8835146662324888" CI_START="-0.8235146662324891" DF="0.0" EFFECT_SIZE="0.029999999999999805" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.01" NO="1" P_CHI2="1.0" P_Z="0.9450769040991155" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.00000000000001" Z="0.06889034466829537">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="0.8835146662324888" CI_START="-0.8235146662324891" EFFECT_SIZE="0.029999999999999805" ESTIMABLE="YES" MEAN_1="3.26" MEAN_2="3.23" ORDER="92959" SD_1="1.67" SD_2="1.53" SE="0.4354746683943703" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8194293850768896" CI_START="-1.1394293850768897" DF="0.0" EFFECT_SIZE="-0.16000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.02" NO="2" P_CHI2="1.0" P_Z="0.7488314683812813" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.3201805482911771">
<NAME>24 week follow up</NAME>
<CONT_DATA CI_END="0.8194293850768896" CI_START="-1.1394293850768897" EFFECT_SIZE="-0.16000000000000014" ESTIMABLE="YES" MEAN_1="2.84" MEAN_2="3.0" ORDER="92960" SD_1="1.84" SD_2="1.83" SE="0.4997180523736679" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5735971504764756" CI_END="-0.03696715334290501" CI_START="-0.366083962782638" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2015255580627715" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" NO="3" P_CHI2="0.44883315910023747" P_Q="0.44883315910023747" P_Z="0.016383463169356557" Q="0.5735971504764756" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="52" UNITS="" WEIGHT="200.0" Z="2.4002592662450803">
<NAME>Morning stiffness (0-3)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.018615161726291407" CI_START="-0.5413848382737086" DF="0.0" EFFECT_SIZE="-0.28" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.01" NO="1" P_CHI2="1.0" P_Z="0.03576865444001856" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="2.09954762217903">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="-0.018615161726291407" CI_START="-0.5413848382737086" EFFECT_SIZE="-0.28" ESTIMABLE="YES" MEAN_1="1.03" MEAN_2="1.31" ORDER="92961" SD_1="0.51" SD_2="0.47" SE="0.13336206192332045" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.061800814894330786" CI_START="-0.3618008148943306" DF="0.0" EFFECT_SIZE="-0.1499999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.02" NO="2" P_CHI2="1.0" P_Z="0.1651153849033317" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="1.3880711357398907">
<NAME>24 week follow up</NAME>
<CONT_DATA CI_END="0.061800814894330786" CI_START="-0.3618008148943306" EFFECT_SIZE="-0.1499999999999999" ESTIMABLE="YES" MEAN_1="1.12" MEAN_2="1.27" ORDER="92962" SD_1="0.33" SD_2="0.45" SE="0.10806362594669519" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.30025745375337987" CI_END="0.08654178481676184" CI_START="-0.48279455993622483" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1981263875597315" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.04" NO="4" P_CHI2="0.5837211558264327" P_Q="0.5837211558264327" P_Z="0.1725308659910646" Q="0.30025745375337987" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="52" UNITS="" WEIGHT="200.0" Z="1.3641166160666447">
<NAME>Patient global evaluation of disease activity (1-5)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.11357113745269615" CI_START="-0.6535711374526962" DF="0.0" EFFECT_SIZE="-0.27" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.01" NO="1" P_CHI2="1.0" P_Z="0.16769736114083225" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="1.3796404999087737">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="0.11357113745269615" CI_START="-0.6535711374526962" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="1.92" MEAN_2="2.19" ORDER="92963" SD_1="0.85" SD_2="0.57" SE="0.1957031560162617" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3147312029662102" CI_START="-0.5347312029662099" DF="0.0" EFFECT_SIZE="-0.10999999999999988" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.02" NO="2" P_CHI2="1.0" P_Z="0.6117297974295142" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.5076058382189492">
<NAME>24 week follow up</NAME>
<CONT_DATA CI_END="0.3147312029662102" CI_START="-0.5347312029662099" EFFECT_SIZE="-0.10999999999999988" ESTIMABLE="YES" MEAN_1="2.12" MEAN_2="2.23" ORDER="92964" SD_1="0.72" SD_2="0.86" SE="0.21670357532915685" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.19350039240480416" CI_END="0.6442922795896475" CI_START="-0.5089464050302182" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.06767293727971474" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.05" NO="5" P_CHI2="0.6600191087705638" P_Q="0.6600191087705638" P_Z="0.8180728076630246" Q="0.19350039240480416" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="52" UNITS="" WEIGHT="200.0" Z="0.2300244026933574">
<NAME>Schober test (cm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7293492773792601" CI_START="-0.8293492773792598" DF="0.0" EFFECT_SIZE="-0.04999999999999982" ESTIMABLE="YES" I2="0.0" ID="CMP-006.05.01" NO="1" P_CHI2="1.0" P_Z="0.8999348722929449" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.12574361980105211">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="0.7293492773792601" CI_START="-0.8293492773792598" EFFECT_SIZE="-0.04999999999999982" ESTIMABLE="YES" MEAN_1="3.56" MEAN_2="3.61" ORDER="92965" SD_1="1.46" SD_2="1.46" SE="0.3976344889634032" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.028297087873273E-33" CI_END="1.067112015437817" CI_START="-0.647112015437817" DF="0.0" EFFECT_SIZE="0.21" ESTIMABLE="YES" I2="100.0" ID="CMP-006.05.02" NO="2" P_CHI2="0.0" P_Z="0.6310791769920676" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.4802084550677638">
<NAME>24 weeks</NAME>
<CONT_DATA CI_END="1.067112015437817" CI_START="-0.647112015437817" EFFECT_SIZE="0.20999999999999996" ESTIMABLE="YES" MEAN_1="4.12" MEAN_2="3.91" ORDER="92966" SD_1="1.46" SD_2="1.73" SE="0.4373100843681859" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.40458033664935633" CI_END="1.8394066577400374" CI_START="-0.7274536633243965" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5559764972078204" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" NO="6" P_CHI2="0.5247332240605862" P_Q="0.5247332240605862" P_Z="0.3958545488384333" Q="0.40458033664935633" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="52" UNITS="" WEIGHT="200.0" Z="0.8490480777903678">
<NAME>Fingertip-to-floor</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.97439853829809" CI_START="-0.9143985382980904" DF="0.0" EFFECT_SIZE="1.0299999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.01" NO="1" P_CHI2="1.0" P_Z="0.29915582016090714" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="1.0382454339033065">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="2.97439853829809" CI_START="-0.9143985382980904" EFFECT_SIZE="1.0299999999999998" ESTIMABLE="YES" MEAN_1="3.76" MEAN_2="2.73" ORDER="92967" SD_1="4.04" SD_2="3.23" SE="0.9920582998643126" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.8984880536774618" CI_START="-1.5184880536774619" DF="0.0" EFFECT_SIZE="0.18999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.02" NO="2" P_CHI2="1.0" P_Z="0.8274552151121889" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="99.99999999999999" Z="0.21796649748943034">
<NAME>24 weeks</NAME>
<CONT_DATA CI_END="1.8984880536774618" CI_START="-1.5184880536774619" EFFECT_SIZE="0.18999999999999995" ESTIMABLE="YES" MEAN_1="2.82" MEAN_2="2.63" ORDER="92968" SD_1="3.09" SD_2="3.3" SE="0.8716935959812514" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.026319123253617554" CI_END="0.6232081075437009" CI_START="-0.6900541869241458" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.033423039690222436" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.07" NO="7" P_CHI2="0.871123422692982" P_Q="0.871123422692982" P_Z="0.9205319259154976" Q="0.026319123253617554" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="52" UNITS="" WEIGHT="200.0" Z="0.09976370192404486">
<NAME>Chest expansion</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7847574173660291" CI_START="-0.9447574173660275" DF="0.0" EFFECT_SIZE="-0.07999999999999918" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.01" NO="1" P_CHI2="1.0" P_Z="0.8561170404154411" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.18131919497238008">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="0.7847574173660291" CI_START="-0.9447574173660275" EFFECT_SIZE="-0.07999999999999918" ESTIMABLE="YES" MEAN_1="4.94" MEAN_2="5.02" ORDER="92969" SD_1="1.62" SD_2="1.62" SE="0.44121087131555703" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.039095457104859" CI_START="-0.9790954571048602" DF="0.0" EFFECT_SIZE="0.02999999999999936" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.02" NO="2" P_CHI2="1.0" P_Z="0.9535344102050679" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.058268936919899664">
<NAME>24 weeks</NAME>
<CONT_DATA CI_END="1.039095457104859" CI_START="-0.9790954571048602" EFFECT_SIZE="0.02999999999999936" ESTIMABLE="YES" MEAN_1="4.97" MEAN_2="4.94" ORDER="92970" SD_1="1.88" SD_2="1.9" SE="0.5148540815364342" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04193465172467655" CI_END="1.111877127019263" CI_START="-2.228384599691441" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.558253736336089" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.08" NO="8" P_CHI2="0.8377445016628663" P_Q="0.8377445016628663" P_Z="0.5123823721375439" Q="0.04193465172467655" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="52" UNITS="" WEIGHT="200.0" Z="0.6551326255090295">
<NAME>Occiput Wall distance</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.0867863768717494" CI_START="-2.8267863768717496" DF="0.0" EFFECT_SIZE="-0.3700000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-006.08.01" NO="1" P_CHI2="1.0" P_Z="0.7678587205170151" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.2951769356533178">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="2.0867863768717494" CI_START="-2.8267863768717496" EFFECT_SIZE="-0.3700000000000001" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="2.67" ORDER="92971" SD_1="4.32" SD_2="4.85" SE="1.253485470269131" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5572605440089078" CI_START="-2.997260544008908" DF="0.0" EFFECT_SIZE="-0.72" ESTIMABLE="YES" I2="0.0" ID="CMP-006.08.02" NO="2" P_CHI2="1.0" P_Z="0.5354681261564734" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.6196805510820457">
<NAME>24 weeks</NAME>
<CONT_DATA CI_END="1.5572605440089078" CI_START="-2.997260544008908" EFFECT_SIZE="-0.72" ESTIMABLE="YES" MEAN_1="1.76" MEAN_2="2.48" ORDER="92972" SD_1="3.95" SD_2="4.54" SE="1.1618889744769028" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.039141805168438876" CI_END="0.11182038605110742" CI_START="-0.38329702140433" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.13573831767661126" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.09" NO="9" P_CHI2="0.843168084605737" P_Q="0.843168084605737" P_Z="0.282525588218264" Q="0.039141805168438876" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="52" UNITS="" WEIGHT="200.0" Z="1.0746631403468059">
<NAME>BASFI</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2453879892178093" CI_START="-0.4653879892178093" DF="0.0" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-006.09.01" NO="1" P_CHI2="1.0" P_Z="0.5440833734140491" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.6066497598129913">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="0.2453879892178093" CI_START="-0.4653879892178093" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.61" ORDER="92973" SD_1="0.73" SD_2="0.6" SE="0.1813237345283201" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.18504292256537003" CI_START="-0.5050429225653701" DF="0.0" EFFECT_SIZE="-0.16000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-006.09.02" NO="2" P_CHI2="1.0" P_Z="0.36342629449403985" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.90885573074462">
<NAME>24 weeks</NAME>
<CONT_DATA CI_END="0.18504292256536997" CI_START="-0.5050429225653701" EFFECT_SIZE="-0.16000000000000003" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="0.54" ORDER="92974" SD_1="0.57" SD_2="0.71" SE="0.1760455423094631" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.4541449180058352" CI_END="-0.11533067881074238" CI_START="-0.911686377619326" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5135085282150342" ESTIMABLE="YES" I2="31.231063175507572" I2_Q="31.231063175507572" ID="CMP-006.10" NO="10" P_CHI2="0.22786432007315227" P_Q="0.22786432007315227" P_Z="0.01148254919148996" Q="1.4541449180058352" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="52" UNITS="" WEIGHT="200.0" Z="2.5276599955557173">
<NAME>BASDAI</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.19751669931309535" CI_START="-1.1424833006869046" DF="0.0" EFFECT_SIZE="-0.6699999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-006.10.01" NO="1" P_CHI2="1.0" P_Z="0.005447511188678273" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="2.779306417248436">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="-0.19751669931309535" CI_START="-1.1424833006869046" EFFECT_SIZE="-0.6699999999999999" ESTIMABLE="YES" MEAN_1="1.11" MEAN_2="1.78" ORDER="92975" SD_1="0.77" SD_2="0.98" SE="0.2410673381826363" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6096540489732107" CI_START="-0.869654048973211" DF="0.0" EFFECT_SIZE="-0.13000000000000012" ESTIMABLE="YES" I2="0.0" ID="CMP-006.10.02" NO="2" P_CHI2="1.0" P_Z="0.7304860555706122" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.3444790417140481">
<NAME>24 weeks</NAME>
<CONT_DATA CI_END="0.6096540489732107" CI_START="-0.869654048973211" EFFECT_SIZE="-0.13000000000000012" ESTIMABLE="YES" MEAN_1="1.49" MEAN_2="1.62" ORDER="92976" SD_1="1.37" SD_2="1.4" SE="0.37738144925493916" STUDY_ID="STD-Altan-2006" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Balneotherapy therapy versus fresh water pool</NAME>
<CONT_OUTCOME CHI2="0.022819169866619478" CI_END="1.125275781842334" CI_START="-0.9379319915602407" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0936718951410467" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" NO="1" P_CHI2="0.9886552582376962" P_Q="0.9886552582376962" P_Z="0.8587472996827695" Q="0.022819169866619478" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="42" TOTAL_2="42" UNITS="" WEIGHT="300.0" Z="0.1779690278476293">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7444151357464415" CI_START="-1.7444151357464415" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="99.99999999999999" Z="0.0">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="1.7444151357464415" CI_START="-1.7444151357464415" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="4.4" ORDER="92977" SD_1="2.2" SD_2="2.5" SE="0.8900240767208814" STUDY_ID="STD-Codish-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.5293639044485273E-34" CI_END="1.8102621150112679" CI_START="-1.6102621150112668" DF="0.0" EFFECT_SIZE="0.10000000000000055" ESTIMABLE="YES" I2="100.0" ID="CMP-007.01.02" NO="2" P_CHI2="0.0" P_Z="0.9087620128409435" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="99.99999999999999" Z="0.11460021053715223">
<NAME>one month follow up</NAME>
<CONT_DATA CI_END="1.8102621150112679" CI_START="-1.6102621150112668" EFFECT_SIZE="0.10000000000000053" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="5.1" ORDER="92978" SD_1="2.5" SD_2="2.1" SE="0.8725987459471687" STUDY_ID="STD-Codish-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.1274956444679054" CI_START="-1.7274956444679066" DF="0.0" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.03" NO="3" P_CHI2="1.0" P_Z="0.8388466543141753" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="0.20336896637513333">
<NAME>3 months follow up</NAME>
<CONT_DATA CI_END="2.1274956444679054" CI_START="-1.7274956444679068" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="4.9" ORDER="92979" SD_1="2.7" SD_2="2.5" SE="0.983434215971184" STUDY_ID="STD-Codish-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.08853891235212769" CI_END="1.4814404201822269" CI_START="-0.3085352688141547" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5864525756840361" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.02" NO="2" P_CHI2="0.9566961364220874" P_Q="0.9566961364220874" P_Z="0.19903972748374424" Q="0.08853891235212769" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="42" TOTAL_2="42" UNITS="" WEIGHT="300.0" Z="1.284292221450148">
<NAME>Movement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.4672042006568864" CI_START="-0.8672042006568847" DF="0.0" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.01" NO="1" P_CHI2="1.0" P_Z="0.3469717284792623" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="0.9404793887960801">
<NAME>after treatment</NAME>
<CONT_DATA CI_END="2.4672042006568864" CI_START="-0.8672042006568847" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="5.1" ORDER="92980" SD_1="2.2" SD_2="2.3" SE="0.8506300186164538" STUDY_ID="STD-Codish-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.9488211951768155" CI_START="-0.9488211951768155" DF="0.0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.02" NO="2" P_CHI2="1.0" P_Z="0.49878701269359393" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="0.6763995415945231">
<NAME>one months follow up</NAME>
<CONT_DATA CI_END="1.9488211951768155" CI_START="-0.9488211951768155" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="5.4" ORDER="92981" SD_1="1.8" SD_2="2.1" SE="0.7392080704568718" STUDY_ID="STD-Codish-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.057435987561793" CI_START="-1.057435987561793" DF="0.0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.03" NO="3" P_CHI2="1.0" P_Z="0.5291999465874082" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="0.629227782134542">
<NAME>3 months follow up</NAME>
<CONT_DATA CI_END="2.057435987561793" CI_START="-1.057435987561793" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="5.6" ORDER="92982" SD_1="2.0" SD_2="2.2" SE="0.7946247991527646" STUDY_ID="STD-Codish-2005" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>